



11TH WORLD CONGRESS OF MELANOMA

IN CONJUNCTION WITH

21ST EADO CONGRESS

**APRIL 3-5
2025
ATHENS**

MEGARON ATHENS
INTERNATIONAL
CONFERENCE CENTER



**PRELIMINARY
PROGRAM**

latest update 10/01/2025

ON-SITE CONGRESS WITH ADDITIONAL VIRTUAL ACCESS
WORLDMELANOMA2025.COM

TABLE OF CONTENTS

Welcome Message	5
Congress at a Glance	6
Congress History	7
Congress Venue	8
Floor Plan MAICC	10
Congress Faculty	12
Additional Speaker	16
Call for Abstracts	19
General Information from A-Z	21
Scientific Program at a Glance	26
> April 3 rd , 2025	26
> April 4 th , 2025	30
> April 5 th , 2025	34
Scientific Program	38
> April 3 rd , 2025	38
> April 4 th , 2025	48
> April 5 th , 2025	58
Satellite Symposium Program at a Glance	70
Satellite Symposium Program	72
> April 3 rd , 2025	72
> April 4 th , 2025	74
> April 5 th , 2025	76



IMPORTANT DEADLINES

- **January 15th, 2025:**
Early registration fee deadline

- **January 31st, 2025:**
Start of late-breaking & trials in progress abstract submission


- **February 6th, 2025:**
Deadline for late-breaking & trials in progress abstract submission (6:00 pm CET)

- **February 13th, 2025:**
Notification for abstract acceptance incl. late-breaking & trials in progress abstracts

- **March 3rd, 2025:**
Poster upload deadline

- **October 15th, 2025:**
End of On-Demand service





**11TH WORLD CONGRESS
OF MELANOMA**
IN CONJUNCTION WITH
21ST EADO CONGRESS

CONGRESS PRESIDENTS



Prof. Axel Hauschild
Kiel, Germany



Prof. Claus Garbe
Tuebingen, Germany



Prof. Alexander Stratigos
Athens, Greece

WELCOME MESSAGE

Dear colleagues and friends,

We have the great honour and pleasure to invite you to join us for the **11th World Congress of Melanoma in conjunction with the 21st EADO Congress** which will be held under the auspices of two renowned authorities in the field of continuous medical education, the Melanoma World Society (MWS) and European Association of Dermato-Oncology (EADO).

The World Congress of Melanoma has always been a unique forum of exchange between physicians, scientists, nurses and students. It constitutes a lively exchange of clinical experiences, research work and clinical trial output among experts from all continents reflecting the enormous progress in the field of melanoma and skin cancer. The congress also offers a great opportunity for young colleagues to interact with distinguished faculty, discuss with industry partners and communicate with representatives of patient organizations, creating a formidable learning environment. The 11th World Congress of Melanoma & 21st EADO Congress will be no exception to the rich heritage, reputation and influence of the previous World Congresses.

From a scientific perspective, the program of the conference will provide a comprehensive overview of the most recent advances in melanoma and cutaneous oncology. A variety of plenary lectures, interactive symposia, and workshops will cover the field of **melanoma as well as squamous cell carcinoma, Merkel cell carcinoma, basal cell carcinoma, actinic keratosis, cutaneous sarcomas, adnexal tumors and cutaneous T- and B-cell lymphomas**. The entire spectrum of each disease will be presented including **epidemiology, prevention and early detection, diagnosis and staging, surgical and radiotherapy and systemic and intralesional therapies**. Certain unique elements will be introduced such as special **advocacy sessions** with the participation of invited policymakers, public health professionals and patient organizations. A series of **“interdisciplinary tumor board”** sessions will provide a continuous stream of presentations of interesting or challenging cases with a specific teaching point presented by residents and younger colleagues.

“Socratic dialogues” will also take place in small groups comprised of selected young colleagues from different countries who will be mentored by world-famous experts. Inspired by examples from ancient Greek heritage, the 11th World Congress of Melanoma & 21st EADO Congress will focus on young colleagues, not only serving as a platform of exchanging knowledge but also aiming to a deeply influential effect in their career paths.

Most importantly, the conference will be an opportunity to celebrate the therapeutic milestones achieved in the battle against skin cancer. The meeting will honor the remarkable collective achievements in the field and, through its proceedings, will define the work ahead to the ultimate goal of melanoma cure.

The unique surroundings of the cultural city of Athens and the springtime environment will contribute to what we expect will be a landmark event.

Looking forward to welcoming you in Athens 2025!

CONGRESS AT A GLANCE

Congress Format

On-site congress with additional virtual access

Congress Presidents

Axel Hauschild, Kiel, Germany

Claus Garbe, Tuebingen, Germany

Alexander Stratigos, Athens, Greece

Steering Committee

Paolo Ascierto, Naples, Italy

Jeffrey Gershewald, Houston, USA

Helen Gogas, Athens, Greece

Jun Guo, Beijing, China

Allan C. Halpern, New York, USA

Aimilios Lallas, Thessaloniki, Greece

Georgina Long, Sydney, Australia

Paul Lorigan, Manchester, United Kingdom

Olivier Michielin, Lausanne, Switzerland

Chrysalyn Schmults, Boston, USA

Richard Scolyer, Sydney, Australia

Alexander van Akkooi, Sydney, Australia

Alberto Wainstein, Belo Horizonte, Brazil

Dagmar Whitaker, Cape Town, South Africa

Expected Number of Participants

2,000

Congress Language

English

Congress Venue

Megaron Athens International

Conference Centre

Vas. Sofias & Kokkali

115 21 Athens, Greece

<https://www.megaron.gr/en/>

[international-conference-centre/](https://www.megaron.gr/en/international-conference-centre/)

Congress Website

<https://worldmelanoma2025.com>

Congress Organizer

MEDCONCEPT 

MedConcept GmbH


Friedenstr. 58

15366 Neuenhagen bei Berlin

Germany

Phone: +49 (0) 334242689-30

E-Mail: wcm2025@medconcept.org



- 1985** — Venice, Italy
- 1989** — Venice, Italy
- 1993** — Venice, Italy
- 1997** — Sydney, Australia
- 2001** — Venice, Italy
- 2005** — Vancouver, Canada
- 2009** — Vienna, Austria
- 2013** — Hamburg, Germany
- 2017** — Brisbane, Australia
- 2021** — Virtual Congress
- 2025** — Athens, Greece



- 2001** — Vienna, Austria
- 2003** — Marseille, France
- 2006** — Rome, Italy
- 2008** — Marseille, France
- 2009** — Vienna, Austria
- 2010** — Athens, Greece
- 2011** — Nantes, France
- 2012** — Barcelona, Spain
- 2013** — Hamburg, Germany
- 2014** — Vilnius, Lithuania
- 2015** — Marseille, France
- 2016** — Vienna, Austria
- 2017** — Athens, Greece
- 2018** — Barcelona, Spain
- 2019** — Paris, France
- 2020** — Virtual Congress
- 2021** — Virtual Congress
- 2022** — Seville, Spain
- 2023** — Rome, Italy
- 2024** — Paris, France
- 2025** — Athens, Greece
- 2026** — Prague, Czech Republic
- 2027** — to be announced
- 2028** — Vienna, Austria

CONGRESS HISTORY

World Congresses of Melanoma

In the 1970s, the global melanoma community established a worldwide organization within the WHO, the WHO Melanoma Group. This group initiated a series of international studies, especially in melanoma surgery, that set standards for safety margins in primary melanoma excision and for lymph node surgery. The WHO Melanoma Group also initiated the first World Congress of Melanoma in 1985, which was then held every 4 years. The WHO Melanoma Group held its last meeting at the World Congress of Melanoma 2005 in Vancouver. After that, the Group dissolved because the WHO no longer supported their work.

This is the reason why former members of the WHO Melanoma Group and other worldwide known melanoma experts came together at the World Congress of Melanoma 2013 in Hamburg and founded the Melanoma World Society. At that time, this society set itself the objective of the WHO's previous commitments to the melanoma group, in particular the Organization of the World Congress and other educational congresses on the topic of melanoma. Other goals include supporting global policy development and supporting clinical and scientific research in the world.

EADO Congress

The EADO (European Association of Dermato-Oncology) is an independent non-profit organization dedicated to promote, coordinate and improve clinical and laboratory research activities in the field of skin cancer including primary and secondary prevention, early detection, clinical diagnosis and clinical and experimental research. One mission of the EADO is to support and organise meetings dedicated to the presentation of new research findings, exchange of information and education for its members in the field of dermato-oncology. The first EADO Congress was held 2001 in Vienna, Austria.

11TH WORLD CONGRESS OF MELANOMA

IN CONJUNCTION WITH

21ST EADO CONGRESS



CONGRESS VENUE

The Megaron Athens International Conference Centre (MAICC) is one of the most modern conference venues in Europe, offering flexible spaces, stunning aesthetics and state-of-the-art technology. Located in the centre of Athens, MAICC has a total offering of 143, 000 square metres and a choice of 18 meeting spaces, combined with expansive exhibition and foyer areas.

In addition, the venue offers 750 parking spaces and is located on a direct metro line to the Eleftherios Venizelos International Airport, journey time 35 minutes.




Airport

Athens International Airport "Eleftherios Venizelos", commonly initialised as AIA, is located 33km away from Athens city and the congress venue Megaron Athens International Conference Centre (MAICC).



FLOOR PLAN MAICC



Kokkali Street

Entr

Fuga

Trianti Hall

Atrium

Skalkotas Hall

Conference Suite II


The Banqueting Hall

Muses Upper Foyer

Muses Foyer

Parking level 1, 2, 3

Vass. S



CONGRESS FACULTY

A

Adams David
Cambridge, United Kingdom

Agarwala Sanjiv
Philadelphia, USA

Amaral Teresa
Tuebingen, Germany

Apalla Zoe
Thessaloniki, Greece

Arance Ana
Barcelona, Spain

Arenberger Petr
Prague, Czech, Republic

Argenziano Giuseppe
Naples, Italy

Ascierto Paolo
Naples, Italy

B

Bafaloukos Dimitris
Athens, Greece

Bataille Veronique
London, United Kingdom

Bechrakis Nikolaos
Essen, Germany

Becker Jürgen
Essen, Germany

Berking Carola
Erlangen, Germany

Bhatia Shailender
Seattle, USA

Blank Christian
Amsterdam, The Netherlands

Bosisio Francesca Maria
Leuven, Belgium

Bylaite-Bucinskiene Matilda
Vilnius, Lithuania

C

Coupland Sarah
Liverpool, United Kingdom

D

Davies Michael
Houston, USA

Del Marmol Veronique
Brussels, Belgium

Dessinioti Clio
Athens, Greece

Dirschka Thomas
Wuppertal, Germany

Dréno Brigitte
Nantes, France

Dummer Reinhard
Zurich, Switzerland

E

Eggermont Alexander
Utrecht, The Netherlands

Eigentler Thomas
Berlin, Germany

F

Fargnoli Maria Concetta
Rome, Italy

Forschner Andrea
Tuebingen, Germany

Forsea Ana-Maria
Bucharest, Romania

G

Gajewski Thomas
Chicago, USA

Garbe Claus
Tuebingen, Germany

Gebhardt Christoffer
Hamburg, Germany

Gershenwald Jeffrey
Houston, USA

Geusau Alexandra
Vienna, Austria

Gogas Helen
Athens, Greece

Grabbe Stephan
Mainz, Germany

Griewank Klaus
Essen, Germany

Guenova Emmanuella
Lausanne, Switzerland

Guild Samantha
Richmond, USA

Guo Jun
Beijing, China

Gutzmer Ralf
Minden, Germany

H

Halpern Allan C.
New York, USA

Hamid Omid
Los Angeles, USA

Harwood Catherine
London, United Kingdom

Hassel Jessica
Heidelberg, Germany

Hauschild Axel
Kiel, Germany

Heppt Markus
Erlangen, Germany

Höller Christoph
Vienna, Austria

J

John Swen-Malte
Osnabrueck, Germany

K

Kaminski Katharina
Essen, Germany

Kandolf Lidija
Belgrade, Serbia

Kaufmann Roland
Frankfurt, Germany

Kelleners-Smeets Nicole
Maastricht, The Netherlands

Kinsler Veronica
London, United Kingdom

Kittler Harald
Vienna, Austria

Krasagakis Konstantinos
Heraklion, Greece

L

Lallas Aimilios
Thessaloniki, Greece

Landi Maria Teresa
Bethesda, USA

Lebbé Céleste
Paris, France

Leiter-Stöppke Ulrike
Tuebingen, Germany

Lianidou Evi
Athens, Greece

Liopyris Konstantinos
Athens, Greece

Livingstone Elisabeth
Essen, Germany

Long Georgina
Sydney, Australia

Longo Caterina
Reggio Emilia, Italy

Lorigan Paul
Manchester, United Kingdom

Lugowska Iwona
Warsaw, Poland

M

Malveyh Josep
Barcelona, Spain

Mandalá Mario
Perugia, Italy

Markel Gal
Tel Aviv, Israel

McArthur Grant
Melbourne, Australia

Michielin Olivier
Geneva, Switzerland

Mijuskovic Zeljko
Belgrade, Serbia

Mohr Peter
Buxtehude, Germany

Moreno-Ramirez David
Seville, Spain

Munhoz Rodrigo R.
Sao Paulo, Brazil

N

Nakamura Yasuhiro
Saitama, Japan

Nathan Paul
London, United Kingdom

Neyns Bart
Brussels, Belgium

Nikolaou Viky
Athens, Greece

O

Oláh Judit
Szeged, Hungary

Ortiz Pablo
Madrid, Spain

P

Patel Sapna
Denver, USA

Patton Liz
Edinburgh, United Kingdom

Pellacani Giovanni
Modena, Italy

Petrella Teresa
Toronto, Canada

Plasmeijer Elsemieke
Amsterdam, The Netherlands

Postow Michael
New York, USA

Puig Susana
Barcelona, Spain

Q

Quaglino Pietro
Turin, Italy

R

Robert Caroline
Paris, France

Ross Merrick I.
Houston, USA

Rutkowski Piotr
Warsaw, Poland

Ryll Bettina
Uppsala, Sweden

S

Saiag Philippe
Boulogne, Billancourt France

Schadendorf Dirk
Essen, Germany

Schilling Bastian
Frankfurt, Germany

Schmults Chrysalyne
Boston, USA

Scolyer Richard
Sydney, Australia

Shaw Heather
London, United Kingdom

Sibaud Vincent
Toulouse, France

Sekulic Aleksandar
Phoenix, USA

Situm Mirna
Zagreb, Croatia

Sondak Vernon
Tampa, USA

Stefanaki Irene
Athens, Greece

Stockfleth Eggert
Bochum, Germany

Stratigos Alexander
Athens, Greece

Sullivan Ryan
Boston, USA

Svane Inge Marie
Copenhagen, Denmark

T

Tagliaferri Luca
Rome, Italy

Tawbi Hussein
Houston, USA

Thomas Luc
Lyon, France

Theoxaris Sotirios
Athens, Greece

Trakatelli Myrto
Thessaloniki, Greece

U

Ugurel Selma
Essen, Germany

V

van Akkooi Alexander
Sydney, Australia

Venables Zoe
Norwich, United Kingdom

Vieira Ricardo
Coimbra, Portugal

W

Wainstein Alberto
Belo Horizonte, Brazil

Wargo Jennifer
Houston USA

Weichenthal Michael
Kiel, Germany

Welzel Julia
Augsburg, Germany

Whitaker Dagmar
Cape Town, South Africa

Whiteman David
Brisbane, Australia

Winkler Julia
Heidelberg, Germany

Z

Zalaudek Iris
Trieste, Italy

Zimmer Lisa
Essen, Germany

Zitvogel Laurence
Paris, France

ADDITIONAL SPEAKER

A

Akay Bengu Nisa
Ankara, Turkey

Arenbergerova Monika
Prague, Czech Republic

Assaf Chalid
Krefeld, Germany

Astratinei Violeta
Amsterdam, The Netherlands

B

Basset-Seguin Nicole
Paris, France

Borch Troels Holz
Copenhagen, Denmark

Brown Kevin
Bethesda, USA

C

Cascone Tina
Houston, USA

Cust Anne
Sydney, Australia

D

Daud Adil
San Francisco, USA

de la Fourchadiere Arnaud
Lyon, France

Di Nardo Lucia
L'Aquila, Italy

Dimitriou Florentia
Houston, USA

E

Elder David
Philadelphia, USA

F

Ferrandiz-Pulido Carla
Barcelona, Spain

Fisher David E.
Boston, USA

Fukushima Satoshi
Kumamoto, Japan

G

Gammage Payam
Glasgow, Scotland

Guild Samantha
Richmond, USA

Gyulai Rolland
Szeged, Hungary

H

Heimann Heinrich
Liverpool, United Kingdom

Helgadottir Hildur
Stockholm, Sweden

I

Ito Takamich
Fukuoka, Japan

J

Jönsson Göran
Lund, Sweden

Jouary Thomas
Bordeaux, France

K

Kaminski Katharina
Essen, Germany

Kölblinger Peter
Salzburg, Austria

L

Landi Maria Teresa
Bethesda, USA

Lazaridou Elizabeth
Thessaloniki, Greece

Lennehan Carrie
Birmingham, USA

Lian Bin
Beijing, China

Lo Roger
Los Angeles, USA

Lodde Georg
Essen, Germany

M

Maubec Eve
Bobigny, France

Meier Friedegund
Dresden, Germany

Migden Michael
Houston, USA

Moscarella Elvira
Reggio Emilia, Italy

Mosterd Klara
Maastricht, Netherlands

N

Nagore Eduardo
Valencia, Spain

P

Papadavid Evangelia
Athens, Greece

Patel Vishal
Washington, USA

Pellegrini Cristina
L'Aquila, Italy

Perez Javiera
Barcelona, Spain

Poulikakos Poulikos
New York, USA

Proby Charlotte
Dundee, United Kingdom

R

Rembielak Agata
Manchester, United Kingdom

Robert Caroline
Paris, France

Rossi Elena
Modena, Italy

S

Scarisbrick Julia
Birmingham, United Kingdom

Scaini Maria Chiara
Padova, Italy

Shain Alan Hunter
San Francisco, USA

Smalley Inna
Tampa, USA

Soerjomataram Isabelle
Lyon, France

Soyer Peter
Brisbane, Australia

Starrace Michela Valeria
Bologna, Italy

Stein Deutsch Julia
Baltimore, USA

Suijkerbuijk Karijn
Utrecht, The Netherlands

Suppa Mariano
Brussels, Belgium

T

Tasdogan Alpaslan
Essen, Germany

Taube Janis
Baltimore, USA

Theoxaris Sotirios
Athens, Greece

U

Uhara Hisashi
Sapporo, Japan

V

Visser Willie
Stellenbosch, South Africa

Vossaert Katrien
Gent, Belgium

W

Weinlich Georg
Innsbruck, Austria

Wilmott James
Sydney, Australia

Wojcieszek Piotr
Gliwice, Poland

Wong Michael K.
Houston, USA

Z

Zaremba Anne
Essen, Germany

CALL FOR ABSTRACTS

Abstract Submission Deadline:
January 15, 2025 (6:00 pm CET)

All those interested in presenting abstracts at the 11th World Congress of Melanoma & 21st EADO Congress are invited to submit their work to the Program Committee for review. Selected abstracts will be chosen for an oral presentation during the free communications sessions or as e-posters for virtual consultation. The acceptance of an abstract does not include the congress registration. Authors must be registered for the congress until February 14, 2025 in order to present their work.

Abstract Topics

- › Actinic keratoses
- › Basal cell carcinoma
- › Cutaneous sarcoma
- › Cutaneous T- and B-cell lymphoma
- › Melanoma – Epidemiology and diagnostics
- › Melanoma – Experimental and translational studies
- › Melanoma – Immune checkpoint inhibitor (ICI) therapy
- › Melanoma – Surgery
- › Melanoma – Systemic therapy other than ICI therapy
- › Merkel cell carcinoma
- › Rare tumors
- › Squamous cell carcinoma

Abstract Guidelines

- › Abstracts may be **submitted online via the congress website**. Abstracts submitted by e-mail will not be accepted.
- › Abstracts must be received by the **announced deadline**. Abstracts received after the deadline will not be considered.
- › The **title** should be as brief as possible but long enough to clearly indicate the nature of the study. Abbreviations must not be used in the title. The title should not be written entirely in capital letters (e.g. NOT LIKE THIS).
- › Please indicate the **topic** from the abstract topics list and your preferred type of presentation (oral or poster). The Committee will endeavor to schedule abstracts according to authors' preferences but reserves the right to decide on the final form of presentation.
- › **Encore abstracts** will be accepted unless they have been published in scientific journals.
- › Please structure the abstract as follows:
 - **Introduction & Objectives:** Describe the background and the purpose of the study
 - **Materials & Methods:** Describe the material and methods used to design the study
 - **Results:** Describe your results in a logical sequence
 - **Conclusions:** Emphasise new and important aspects of the study and conclusions that are drawn from them

IMPORTANT DEADLINES



››› **January 15, 2025:**
 Deadline for abstract submission (6:00pm CET)

››› **January 31, 2025:**
 Start of late-breaking & trials in progress abstract submission

››› **February 6, 2025:**
 Deadline for late-breaking & trials in progress abstract submission (6:00pm CET)

››› **February 13, 2025:**
 Notification of acceptance of abstracts including late-breaking & trials in progress abstracts

››› **March 3, 2025:**
 Poster Upload Deadline

- ▶ The text shall not exceed 350 words including spaces (excluding title, authors bibliography and key words). The submission program will automatically calculate the number of characters in your abstract and will not allow submissions that exceed the maximum number of characters.
- ▶ It is acceptable to include up to two **tables, graphics, or images (jpg, jpeg, png, gif format, maximum size 2 MB in total)** as part of the abstract.
- ▶ All abstracts must be submitted and presented in clear **English** with accurate grammar and spelling of a quality suitable for publication. Abstracts will not be edited by the Congress Secretariat prior to publication, therefore please check the grammar and spelling carefully.
- ▶ Please use generic names. **The use of commercial drug names, brands and registered trademarks are strictly prohibited.** Drugs should be referred to by the active substance or pharmacological designation.
- ▶ No mention of pharmaceutical company names should be included in the abstract.

Patient Privacy/Clinical Photography

Photographs should at all times protect the privacy and identity of the subject. Eyes should be blacked out. The source of the photographs must also be declared if not the property of the presenter. This is to prevent the use of photographic material without permission.

Oral Presentations

Selected abstracts will be chosen for an oral presentation during the free communications sessions. The presenting author does not have to be the first author.

Poster Presentation

Abstracts selected for poster will be presented as printed posters during the congress. Further information will be provided prior to the congress.

Publication

All accepted abstracts will be published in the digital Book of Abstracts which will be available for download on the congress website from March 15, 2025 onwards. The Book of Abstract will also be published on the EADO website under Events & Training/EADO Congress after the conference.

Registration

Please note that the acceptance of an abstract does not include the congress registration. The presenting author must be a registered participant, otherwise the abstract will not be reviewed and waived from the program.

Abstract Awards

Further information will be available soon.

GENERAL INFORMATION FROM A-Z

Accommodation

Further information will be available soon.

Badges

The name badge is the official congress identification document. Please wear your badge at all times in order to gain entry into the session rooms and exhibition area. Admission to the congress area will not be permitted without badge identification. Kindly note that for the reprinting of lost or forgotten badges, an administrative fee of 20 Euro will be charged.

Cancellation Policy

Cancellations must be received in writing to registrations@worldmelanoma2025.com by February 14, 2025. No refunds will be granted after that date. A processing fee of 30 Euro will be deducted from each cancelled/amended registration. Substitutions are possible. To substitute a registration, please send an email including the name of the original registrant and the name of the person substituting to registrations@worldmelanoma2025.com.

Certificate of Attendance

For the download of the certificate of attendance and the CME certificate you will receive an email with a link for download after the congress. Before downloading your certificate, you must answer the official EACCME questionnaire.

Cloakroom and Luggage

Further information will be available soon.

CME Credits

In order to receive the CME points, please have your name badge scanned daily. This serves to record your attendance and the corresponding allocation of the CME points. You will receive your certificates of attendance by e-mail after the event. (Please note that you will need to fill in the official EACCME questionnaire, which you will also receive by e-mail after the congress).

Congress Bag

Congress bags can be picked up at the registration desk. Each bag contains a copy of the Congress Program at a Glance and other useful information.

Congress Program

Please note that there will be no printed program provided on-site for sustainability reasons. You may find the printed Program at a Glance in your congress bag. The full program can be viewed via the congress app or can be downloaded as a pdf from the congress website. All registered delegates will receive further information by email shortly before the congress. Delegates may also scan the QR code available at the Registration Desk using their iPhone or Android.



CONGRESS ORGANIZATION

MEDCONCEPT

Gesellschaft für medizinische
Projekte mbH
Friedenstr. 58
15366 Neuenhagen bei Berlin
Germany

Phone +49 (0)3342 - 42 68 930

E-Mail: wcm2025@medconcept.org
www.medconcept.org

Congress Venue

Megaron Athens International Conference Centre
Vas. Sofias & Kokkali
115 21 Athens, Greece
<https://www.megaron.gr/en/international-conference-centre/>



Exhibition

A commercial exhibition will run during the congress. Visit the onsite industrial exhibition to get in touch with exhibitors, colleagues, collaborators and friends. As soon as available, you can view the booth plan via the congress website <https://worldmelanoma2025.com> (from the end of 2024).

Exhibition Opening Hours

Further information will be available soon.

First Aid

In case of emergency, please go to the First Aid room.
The Greek number for the ambulance service is 166.

Insurance

The organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect of health and travel insurance.

Language and Translation

The official language of the meeting is English. Simultaneous translation will not be provided.

Liability Disclaimer

In the unlikely occurrence that the congress must be cancelled or postponed due to circumstances beyond the control of the organizers (natural disasters, political, social or economic events or other unforeseen events beyond control), the organizers cannot be held liable for any costs incurred by the event attendee. The organizer will record images during the event. By virtue of attendance, attendees agree to the organizer's usage of these recordings on the website and for marketing.

Lost & Found

Please hand in all found items at the registration desk. A lost and found box will be provided there.

Lunches and Refreshments

Coffee breaks and lunch will be served in the exhibition area on the ground floor. It is not allowed to bring food into the Amphitheatre/Meeting Rooms.

Parking Facilities

The venue offers 600 parking spaces which are open daily from 06:00am–02:00am.

Program Changes

The organizer reserves the right to make changes to the event program at short notice if necessary. This does not result in any reimbursement claims. Program changes will be announced during the congress.

Questions to Speakers

Questions can be asked online via the congress app. In addition to that wireless microphones will be available during the discussion period in all sessions. Delegates wishing to participate in the discussion periods should make their way to the nearest microphone placed in the aisles.

Registration

Registration is only possible by using the online portal on the congress website. Further information will follow soon. For group bookings, there will be a group booking portal on the congress website.

Category/Fee	Regular & Onsite Fee On-Site	Early Bird Fee On-Site	Virtual Attendance
	Attendance from January 16 th , 2025	Attendance until January 15 th , 2025	
Full Delegate/ Non-EADO Member	800 €	700 €	700 €
EADO Member	700 €	600 €	600 €
“Resident/Trainee/Medical Fellow Scientist/Allied Health Professional/Nurse*”	500 €	400 €	400 €
Student*	250 €	200 €	200 €
Day Tickets**	350 €	250 €	-

* The resident/student registration rate will be granted only after receipt of proof. The written proof of status (e.g. letter signed by the head of department confirming the status of the applicant/copy of student ID card) can be uploaded online during the registration process.

** Virtual participation and the on-demand service are not included in the day tickets.

Method of payment:

Only credit cards (Visa, MasterCard, American Express and PayPal) will be accepted. Bank transfers are only possible in exceptional cases for group bookings/hospitals. Please note that in payments by bank transfers, the bank charges must be paid by the delegate.

On-site registration fee covers:

- › Admission to on-site & virtual scientific sessions and satellite symposia
- › Admission to the on-site & virtual industrial exhibition
- › On-site coffee breaks
- › Congress bag
- › Opening ceremony
- › Certificate of attendance
- › Book of abstracts
- › Login to the on-demand area (session files will be available until October 15, 2025)

Virtual registration fee covers:

- › Admission to virtual streaming of scientific sessions and satellite symposia
- › Admission to virtual industrial exhibition
- › Virtual opening ceremony

- › Certificate of attendance
- › Book of abstracts
- › Login to the on-demand area (session files will be available until October 15, 2025)

Registration Desk

The registration desk is situated on the ground floor.
Further information will be available soon.

Smoking

Smoking is strictly forbidden within the congress center.

Social Networks

Stay tuned and connected and follow the conference on Instagram and Facebook.



Further information will be available soon.



Further information will be available soon.

Speaker Preview Room

A Speakers' Preview Room is provided for all speakers. All presentations must be downloaded in the Speakers' Preview Room beforehand, as the presentations will be sent directly to the meeting room through the internal computer network.

The following facilities will be provided in the room: computers (Windows operating system) to review, alter and upload the presentations to the server and support by technical staff.

The presentations should be handed into the Speakers' Preview Room **at least two hours before the session**. Speakers with a presentation during the first time slot of the morning are kindly asked to hand in their presentation the day before. All speakers will be able to find their presentations easily on the preview monitor on the lectern in the corresponding session room.

Sustainability

Sustainability is more important today than ever before. We are working internally on increasing our sustainability efforts and would like to encourage all involved in the 11th World Congress of Melanoma in conjunction with the 21st EADO Congress to minimize their environmental and social impacts. Go Green – Acting today for tomorrow!

Ways to get involved:

- › Travel by train/by carbon offsetting your flights to Athens and encourage your colleagues to do the same
- › Use the recycling bins provided on-site
- › Recycle your name-badge in the bin provided at the registration desk
- › Recycle all brochures and promotional items not needed in the bin provided within the industrial exhibition
- › Use the public transportation system in Athens.

Welcome Reception

All registered delegates are invited to join the welcome reception on Thursday, April 3, 2025 from 18:00–20:00 which will be held within the exhibition area. The Welcome Reception is open to all registered delegates, sponsors and exhibitors.

Time Zone

Athens is in the Eastern European Time Zone which is 2 hour ahead of Greenwich Mean Time (GMT +2). Like most states in Europe, Athens observes daylight saving (summer time). On Sunday, March 30, 2025 time will be shifted forward by 1 hour (GMT+3)

Weather

In April, the temperatures during the day in Athens range between 12 °C and 20 °C. However, the daily average temperature for Athens during April is around 18 °C.

Wi-Fi

Free Wi-fi will be available within the congress area. Further information will be available soon.



SCIENTIFIC PROGRAM AT A GLANCE

THURSDAY, APRIL 3RD, 2025

	Trianti Hall 1,500 seats/Ground Level	Banqueting Hall 650 seats/Level -2	Mitropoulos Hall 450 seats/Old Building
08:00	Opening Ceremony		
09:00	SYMPOSIUM SY01 Controversies – Skin cancer screening should be abandoned!	SYMPOSIUM SY02 Dermoscopy 1: Total body photography, digital dermoscopy and scanners: indications and procedures	SYMPOSIUM SY03 Prognostic and predictive biomarkers in melanoma
10:00	SYMPOSIUM SY06 Controversies – Does melanoma follow-up contribute to overall survival improvement?	SATELLITE SYMPOSIUM SAT01 Gold Sponsor	SYMPOSIUM SY07 Melanoma guidelines around the world
	Break		
11:00	KEYNOTE LECTURE KEY01 Skin cancer epidemic: is there light at the end of the tunnel?		
	KEYNOTE LECTURE KEY02 The journey from melanocytes to melanoma		
12:00	SATELLITE SYMPOSIUM SAT02 Platinum Sponsor		
13:00	Break		
14:00			

Skalkotas Hall 380 seats/Level -1	M3 180 seats/Level -1	M2 150 seats/Level -1	
			08:00
SYMPOSIUM SY04 Squamous cell carcinoma: epidemiology and management	SYMPOSIUM SY05 Merkel cell carcinoma: epidemiology, surgery and radiology		09:00
SYMPOSIUM SY08 Intralesional therapies of skin cancer	SYMPOSIUM SY09 Liquid biopsy as a decision maker in melanoma?		10:00
			11:00
			12:00
			13:00
			14:00

THURSDAY, APRIL 3RD, 2025

	Trianti Hall 1,500 seats/Ground Level	Banqueting Hall 650 seats/Level -2	Mitropoulos Hall 450 seats/Old Building
14:00	SYMPOSIUM SY10 Melanoma classifications: past, present and future	SATELLITE SYMPOSIUM SAT03 Gold Sponsor	SYMPOSIUM SY11 Treatment of cutaneous lymphomas: what's coming from the pipeline?
15:00	SYMPOSIUM SY15 Neoadjuvant treatment of melanoma	SYMPOSIUM SY16 Basal cell carcinoma: epidemiology and management	SATELLITE SYMPOSIUM SAT04 Silver Sponsor SATELLITE SYMPOSIUM SAT05 Silver Sponsor
16:00	Break		
17:00	SYMPOSIUM SY19 Artificial Intelligence in dermato-oncology	SYMPOSIUM SY20 Registries for real world treatment data and outcome research	SATELLITE SYMPOSIUM SAT06 Further Sponsor
18:00			
19:00	Welcome Reception		
20:00			

Skalkotas Hall 380 seats/Level -1	M3 180 seats/Level -1	M2 150 seats/Level -1	
SYMPOSIUM SY12 Adoptive T-Cell transfer (TILs) for advanced melanomas	SYMPOSIUM SY13 Interdisciplinary tumor board: challenging skin cancer cases I	SYMPOSIUM SY14 Overdiagnosis of melanoma: a real problem?	14:00
SYMPOSIUM SY17 Immunotherapy of Merkel cell carcinoma	SYMPOSIUM SY18 Primary ocular melanoma: genetics, clinical appearance and treatment	FREE COMMUNICATION I	15:00
16:00			
SYMPOSIUM SY21 Memorial Symposium for Jeff Weber Drug resistance to immune checkpoint inhibition	SYMPOSIUM SY22 Skin Care in Organ Transplant Patients Europe (SCOPE)	FREE COMMUNICATION II	17:00
18:00 19:00 20:00			

SCIENTIFIC PROGRAM AT A GLANCE

FRIDAY, APRIL 4TH, 2025

Trianti Hall
1,500 seats/Ground Level

Banqueting Hall
650 seats/Level -2

Mitropoulos Hall
450 seats/Old Building

07:00

08:00

**SOCRATES' DIALOGUES I:
AN INTERACTIVE MORNING
SESSION**

The role of microbiome for immunotherapies

Break

09:00

SYMPOSIUM SY23
Melanoma research

SYMPOSIUM SY24
Congenital nevi:
risk and management

SATELLITE SYMPOSIUM SAT07
Silver Sponsor

10:00

SYMPOSIUM SY27
Controversies – Is there a future
for sentinel node biopsy?

SATELLITE SYMPOSIUM SAT09
Gold Sponsor

SYMPOSIUM SY28
Drug resistance to
targeted therapies

Break

11:00

SYMPOSIUM SY31
Adjuvant treatment of
melanoma

SYMPOSIUM SY32
Management of brain
metastasis

SATELLITE SYMPOSIUM SAT10
Further Sponsor

12:00


SATELLITE SYMPOSIUM SAT11
Platinum Sponsor

13:00

<p>Skalkotas Hall 380 seats/Level -1</p>	<p>M3 180 seats/Level -1</p>	<p>M2 150 seats/Level -1</p>	
			07:00
<p>SOCRATES' DIALOGUES II: AN INTERACTIVE MORNING SESSION Treatment refractory stage IV melanomas: what do I do?</p>	<p>SOCRATES' DIALOGUES III: AN INTERACTIVE MORNING SESSION Women in dermato-oncology</p>		
			08:00
<p>SYMPOSIUM SY25 Management of mucosal melanoma</p>	<p>SYMPOSIUM SY26 Microbiome in cancer: more than gut feelings?</p>	<p>FREE COMMUNICATIONS III</p>	09:00
<p>SYMPOSIUM SY29 Molecular tumor board for skin cancers</p>	<p>SYMPOSIUM SY30 Treatment of field cancerization including actinic cheilitis</p>		10:00
			11:00
<p>SYMPOSIUM SY33 Radiotherapy for melanoma and other skin cancers: where are we now?</p>	<p>SYMPOSIUM SY34 Surgical pearls in the treatment of skin cancer</p>	<p>SYMPOSIUM SY35 Rare skin tumors (adnexal, sebaceous, DFSP)</p>	12:00
			13:00

FRIDAY, APRIL 4TH, 2025

	Trianti Hall 1,500 seats/Ground Level	Banqueting Hall 650 seats/Level -2	Mitropoulos Hall 450 seats/Old Building
13:00	Break		
14:00	KEYNOTE LECTURE KEY03 Diagnostic tools for skin cancer detection beyond dermoscopy		
15:00	KEYNOTE LECTURE KEY04 New diagnostics, prognostic biomarkers and systemic therapy strategies sharply reduce the need for surgery in melanoma		
16:00	SATELLITE SYMPOSIUM SAT12 Platinum Sponsor		
17:00	SYMPOSIUM SY36 Immune checkpoint inhibition for non-melanoma skin cancer	SYMPOSIUM SY37 High-risk melanocytic nevi: are they existing, and how to define what to do?	SATELLITE SYMPOSIUM SAT13 Further Sponsor
18:00	SYMPOSIUM SY41 Global epidemiologic trends and survival in skin cancer	SYMPOSIUM SY42 Immunotherapies of metastatic ocular melanoma in first- and second line	SATELLITE SYMPOSIUM SAT14 Further Sponsor
19:00			



SCIENTIFIC PROGRAM AT A GLANCE

SATURDAY, APRIL 5TH, 2025

	Trianti Hall 1,500 seats/Ground Level	Banqueting Hall 650 seats/Level -2	Mitropoulos Hall 450 seats/Old Building
07:00			
08:00			SOCRATES' DIALOGUES IV: AN INTERACTIVE MORNING SESSION How to build up a career in dermato-oncology?
	Break		
09:00	KEYNOTE LECTURE KEY05 Neoadjuvant therapy: a new standard of care for melanoma?		
10:00	SYMPOSIUM SY45 Primary prevention of skin cancer	SYMPOSIUM SY46 Is there a future for sentinel node biopsy?	SATELLITE SYMPOSIUM SAT15 Further Sponsor
	Break		
11:00	KEYNOTE LECTURE KEY06 Improving outcomes in melanoma beyond the standard use of immune checkpoint blockers		
	KEYNOTE LECTURE KEY07 The future of non-melanoma skin cancer treatment		
12:00	SYMPOSIUM SY49 New devices for ...	SYMPOSIUM SY50 Management of adverse events in immuno-oncology	SATELLITE SYMPOSIUM SAT16 Further Sponsor
	POSTER AWARDS		
13:00	Break		

Skalkotas Hall
380 seats/Level -1

M3
180 seats/Level -1

M2
150 seats/Level -1

07:00

**SOCRATES' DIALOGUES V:
AN INTERACTIVE MORNING
SESSION**

Prognostic and predictive
biomarkers for melanoma

**SOCRATES' DIALOGUES VI:
AN INTERACTIVE MORNING
SESSION**

Challenges in neoadjuvant
therapy

08:00

SYMPOSIUM SY47

Patient Advocacy Groups

SYMPOSIUM SY48

Interdisciplinary tumor board:
challenging skin cancer cases II

09:00

10:00

SYMPOSIUM SY51

Promising agents for
PD1-refractory patients

SYMPOSIUM SY52

Melanoma pathology –
genomics and morphology

FREE COMMUNICATIONS IV

11:00

12:00

13:00

SATURDAY, APRIL 5TH, 2025

Trianti Hall 1,500 seats/Ground Level	Banqueting Hall 650 seats/Level -2	Mitropoulos Hall 450 seats/Old Building
---	--	---

13:00

Break

14:00

SYMPOSIUM SY53

Treatment at the end of the life

SYMPOSIUM SY54

Management of adverse events in targeted therapies

SYMPOSIUM SY55

Management of lentigo maligna and acral lentiginous melanomas

15:00

SYMPOSIUM SY59

Dermoscopy 2: Dermoscopy in melanoma management

SYMPOSIUM SY60

Actinic keratosis: current treatment and future perspectives

SATELLITE SYMPOSIUM SAT17

Further Sponsor

16:00

SYMPOSIUM SY63

Dermoscopy 3: Difficult clinical scenarios

SYMPOSIUM SY64

Surgery of stage IV melanoma: still needed?

SATELLITE SYMPOSIUM SAT18

Further Sponsor

Farewell & Closing Remarks

17:00

18:00

19:00

Skalkotas Hall 380 seats/Level -1	M3 180 seats/Level -1	M2 150 seats/Level -1	
			13:00
SYMPOSIUM SY56 Immune checkpoint inhibition in immunocompromised patients	SYMPOSIUM SY57 Melanocytic lesions of unknown potential: biology, prognosis, treatment and follow-up	SYMPOSIUM SY58 Cutaneous melanoma risk and progression in Mediterranean populations and beyond (MelaNostrum)	14:00
SYMPOSIUM SY61 Diagnosis and management of cutaneous T-and B-cell lymphomas	SYMPOSIUM SY62 Interdisciplinary tumor board: challenging skin cancer cases III		15:00
SYMPOSIUM SY65 Current primary staging and follow-up recommendations for melanoma patients	SYMPOSIUM SY66 Genetic susceptibility of melanoma and cancer syndromes		16:00
			17:00
			18:00
			19:00

SCIENTIFIC PROGRAM

THURSDAY, APRIL 3RD, 2025

08:00–08:15	Trianti Hall	OPENING CEREMONY Alexander Stratigos, Athens, Greece
08:15–09:15	Trianti Hall	SYMPOSIUM SY01 Controversies – Skin cancer screening should be abandoned! CHAIRS: Claus Garbe, Tuebingen, Germany Alexander Stratigos, Athens, Greece Yes: Susana Puig, Barcelona, Spain No: Peter Mohr, Buxtehude, Germany
08:15–09:15	Banqueting Hall	SYMPOSIUM SY02 Dermoscopy 1: Total body photography, digital dermoscopy and scanners: indications and procedures CHAIRS: Harald Kittler, Vienna, Austria Josep Malvehy, Barcelona, Spain 08:15–08:30 Innovative advances in total body photography Josep Malvehy, Barcelona, Spain 08:35–08:50 Artificial intelligence-assisted sequential imaging for high-risk patients Harald Kittler, Vienna, Austria 08:55–09:10 Population screening using total body imaging Katrien Vossaert, Gent, Belgium
08:15–09:15	Mitropoulos Hall	SYMPOSIUM SY03 Prognostic and predictive biomarkers in melanoma CHAIRS: Christian Blank, Amsterdam, The Netherlands Bastian Schilling, Frankfurt, Germany 08:15–08:30 What are biomarkers worth in a changing early stage disease treatment landscape? Christian Blank, Amsterdam, The Netherlands 08:35–08:50 Biomarkers and extra-cutaneous melanoma Bastian Schilling, Frankfurt, Germany 08:55–09:10 Biomarkers of toxicity from targeted and immunotherapy Vincent Sibaud, Toulouse, France

08:15–09:15	Skalkotas Hall	<p>SYMPOSIUM SY04 Squamous cell carcinoma (SCC): epidemiology and management</p> <p>CHAIRS: Chrysalyne Schmults, Boston, USA Ralf Gutzmer, Minden, Germany</p> <p>08:15–08:27 Diagnosis and risk stratification in cutaneous SCC Chrysalyne Schmults, Boston, USA</p> <p>08:30–08:42 Epidemiology of cutaneous SCC Ulrike Leiter-Stöppke, Tuebingen, Germany</p> <p>08:45–08:57 Adjuvant/neoadjuvant treatment of cutaneous SCC Vishal Patel, Washington, USA</p> <p>09:00–09:12 Treatment of cutaneous SCC in the inoperable situation Ralf Gutzmer, Minden, Germany</p>
08:15–09:15	M3	<p>SYMPOSIUM SY05 Merkel cell carcinoma: epidemiology, surgery and radiology</p> <p>CHAIRS: Jürgen Becker, Essen, Germany Shailender Bhatia, Seattle, USA</p> <p>08:15–08:27 Epidemiology Georg Lodde, Essen, Germany</p> <p>08:30–08:42 Surgery Alexander van Akkooi, Sydney, Australia</p> <p>08:45–08:57 Prognostication Jürgen Becker, Essen/Heidelberg, Germany</p> <p>09:00–09:12 Radiotherapy Shailender Bhatia, Seattle, USA</p>
09:15–10:15	Trianti Hall	<p>SYMPOSIUM SY06 Controversies – Does melanoma follow-up contribute to overall survival improvement?</p> <p>CHAIRS: Alexander Eggermont, Utrecht, The Netherlands Ralf Gutzmer, Minden, Germany</p> <p>Yes: Ulrike Leiter-Stöppke, Tuebingen, Germany No: Alexander van Akkooi, Sydney, Australia</p>
09:15–10:15	Banqueting Hall	<p>SATELLITE SYMPOSIUM SAT01 Gold Sponsor</p> <p>Detailed Information Page 70–76</p>

09:15–10:15	Mitropoulos Hall	<p>SYMPOSIUM SY07 Melanoma guidelines around the world</p> <p>CHAIRS: Claus Garbe, Tuebingen, Germany Paolo Ascierto, Naples, Italy Omid Hamid, Los Angeles, USA</p> <p>09:15–09:30 EADO (European Association of Dermato-Oncology) Claus Garbe, Tuebingen, Germany</p> <p>09:30–09:45 ESMO (European Society for Medical Oncology) Paolo Ascierto, Naples, Italy</p> <p>09:45–10:00 NCCN (European Society for Medical Oncology) Omid Hamid, Los Angeles, USA</p> <p>10:00–10:15 JDA (Japanese Dermatological Association) Satoshi Fukushima, Kumamoto, Japan</p>
09:15–10:15	Skalkotas Hall	<p>SYMPOSIUM SY08 Intralesional therapies of skin cancer</p> <p>CHAIRS: Christoph Höller, Vienna, Austria Mario Mandala, Perugia, Italy</p> <p>09:15–09:27 State of the art Michael Migden, Houston, USA</p> <p>09:30–09:42 New targets and systemic immunological activity Adil Daud, San Francisco, USA</p> <p>09:45–09:57 Combining systemic and intralesional therapy: challenges and opportunities Reinhard Dummer, Zurich, Switzerland</p> <p>10:00–10:12 Intralesional neoadjuvant approaches: ready for prime time? Christoph Höller, Vienna, Austria</p>
09:15–10:15	M3	<p>SYMPOSIUM SY09 Liquid biopsy as a decision maker in melanoma?</p> <p>CHAIRS: Christoffer Gebhardt, Hamburg, Germany Evi Lianidou, Athens, Greece Paul Lorigan, Manchester, United Kingdom</p> <p>09:15–09:30 The potential of liquid biopsy for the management of cancer patients Evi Lianidou, Athens, Greece</p> <p>09:35–09:50 Ultra-sensitive tumor-informed ctDNA measurement in melanoma patients receiving checkpoint-inhibition Christoffer Gebhardt, Hamburg, Germany</p> <p>09:55–10:10 Ongoing and potential trials of ctDNA based strategies in melanoma Paul Lorigan, Manchester, United Kingdom</p>

10:15–10:45		Break
10:45–11:15	Trianti Hall	<p>KEYNOTE LECTURE KEY01 CHAIR: Alexander Stratigos, Athens, Greece</p> <p>Skin cancer epidemic: is there light at the end of the tunnel? David Whiteman, Brisbane, Australia</p>
11:15–11:45	Trianti Hall	<p>KEYNOTE LECTURE KEY02 CHAIR: Alexander Stratigos, Athens, Greece</p> <p>The journey from melanocytes to melanoma Alan Hunter Shain, San Francisco, USA</p>
11:45–12:45	Trianti Hall	<p>SATELLITE SYMPOSIUM SAT02 Platinum Sponsor</p> <p>Detailed Information Page 70–76</p>
12:45–13:45		Break
13:45–14:45	Trianti Hall	<p>SYMPOSIUM SY10 Melanoma classifications: past, present and future</p> <p>CHAIRS: Jeffrey Gershenwald, Houston, USA Richard Scolyer, Sydney, Australia</p> <p>13:45–14:00 What is a melanocytoma and how should they be classified and managed? Richard Scolyer, Sydney, Australia</p> <p>14:05–14:20 Beyond the 8th edition American Joint Committee on Cancer (AJCC) melanoma staging system Jeffrey Gershenwald, Houston, USA</p> <p>14:25–14:40 Should we change the term melanoma in situ? David Elder, Pennsylvania, USA</p>
13:45–14:45	Banqueting Hall	<p>SATELLITE SYMPOSIUM SAT03 Gold Sponsor</p> <p>Detailed Information Page 70–76</p>

13:45-14:45	Mitropoulos Hall	<p>SYMPOSIUM SY11 Treatment of cutaneous lymphomas: what's coming from the pipeline?</p> <p>CHAIRS: Emmanuella Guenova, Lausanne, Switzerland Pietro Quaglino, Turin, Italy</p> <p>13:45-14:00 Recently approved treatment approaches Chalid Assaf, Krefeld, Germany</p> <p>14:05-14:20 Products under current clinical developments Pietro Qualigno, Turin, Italy</p> <p>14:25-14:55 Translational evidence: from bench to bedside Emmanuella Guenova, Lausanne, Switzerland</p>
13:45-14:45	Skalkotas Hall	<p>SYMPOSIUM SY12 Adoptive T-Cell transfer (tumor-infiltrating lymphocytes, TIL) for advanced melanomas</p> <p>CHAIRS: Inge Marie Svane, Copenhagen, Denmark Gal Markel, Tel Aviv, Israel</p> <p>13:45-14:00 The art of selecting the right patients for TIL therapy Inge Marie Svane, Copenhagen, Denmark</p> <p>14:05-14:20 The treatment journey and destination of a TIL patient Troels Holz Borch, Copenhagen, Denmark</p> <p>14:25-14:40 What is the next step for TIL therapies? Gal Markel, Tel Aviv, Israel</p>
13:45-14:45	M3	<p>SYMPOSIUM SY13 Interdisciplinary tumor board: challenging skin cancer cases I</p> <p>CHAIRS: Selma Ugurel, Essen, Germany Zeljko Mijuskovic, Belgrade, Serbia Rodrigo Munhoz, Sao Paolo, Brazil</p> <p>13:45-13:57 Case 1 Zeljko Mijuskovic, Belgrad, Serbia</p> <p>14:00-14:12 Case 2 Selma Ugurel, Essen, Germany</p> <p>14:15-14:27 Case 3 Andrea Forschner, Tuebingen, Germany</p> <p>14:30-14:42 Case 4 Rodrigo Munhoz, Sao Paolo, Brazil</p>

13:45-14:45	M2	<p>SYMPOSIUM SY14 Overdiagnosis of melanoma: a real problem?</p> <p>CHAIR: Hensin Tsao, Boston, USA Axel Hauschild, Kiel, Germany</p> <p>13:45-14:00 ...in Europe Josep Malvehy, Barcelona, Spain</p> <p>14:05-14:20 ...in Australia David Whiteman, Brisbane, Australia</p> <p>14:25-14:40 ...in the USA Hensin Tsao, Boston, USA</p>
14:45-15:45	Triantji Hall	<p>SYMPOSIUM SY15 Neoadjuvant treatment of melanoma</p> <p>CHAIRS: Christian Blank, Amsterdam, The Netherlands Georgina Long, Sydney, Australia</p> <p>14:45-14:57 Clinical development of neoadjuvant immunotherapy in melanoma Georgina Long, Sydney, Australia</p> <p>15:00-15:12 Next steps towards full personalization of neoadjuvant melanoma therapy Christian Blank, Amsterdam, The Netherlands</p> <p>15:15-15:27 What can we learn from other cancers? Alexander Eggermont, Utrecht, The Netherlands</p> <p>15:30-15:42 Making the pathological response criteria more efficient and pan-cancer Julie Stein Deutsch, Baltimore, USA</p>
14:45-15:45	Banqueting Hall	<p>SYMPOSIUM SY16 Basal cell carcinoma (BCC): epidemiology and management</p> <p>CHAIRS: Ricardo Vieira, Coimbra, Portugal Clio Dessinioti, Athens, Greece</p> <p>14:45-14:57 Epidemiology of BCC Clio Dessinioti, Athens, Greece</p> <p>15:00-15:12 Topical and interventional management for BCC: recommendations and patient selection Klara Mosterd, Maastricht, The Netherlands</p> <p>15:15-15:27 Surgical management of BCC: case scenarios Ricardo Vieira, Coimbra, Portugal</p> <p>15:30-15:42 The evolution of systemic therapy for advanced BCC Alexander Stratigos, Athens, Greece</p>

14:45–15:15	Mitropoulos Hall	SATELLITE SYMPOSIUM SAT04 Silver Sponsor Detailed Information Page 70–76
15:15–15:45	Mitropoulos Hall	SATELLITE SYMPOSIUM SAT05 Silver Sponsor Detailed Information Page 70–76
14:45–15:45	Skalkotas Hall	SYMPOSIUM SY17 Immunotherapy of Merkel cell carcinoma (MCC) CHAIRS: Céleste Lebbé, Paris, France Iwona Lugowska, Warsaw, Poland 14:45–15:00 The benefits of immunotherapy in non-immunocompromised MCC patients Iwona Lugowska, Warsaw, Poland 15:05–15:20 What is the benefit/risk of immunotherapy in immunosuppressed individuals? Céleste Lebbé, Paris, France 15:25–15:40 Immunotherapy for MCC: do we have prognostic and/or predictive biomarkers? Jürgen Becker, Essen, Germany
14:45–15:45	M3	SYMPOSIUM SY18 Primary ocular melanoma: genetics, clinical appearance and treatment CHAIRS: Nikolaos Bechrakis, Essen, Germany Sarah Coupland, Liverpool, United Kingdom 14:45–15:00 Biology, genetics and pathology of conjunctival and uveal melanomas Sarah Coupland, Liverpool, United Kingdom 15:05–15:20 Diagnosis of conjunctival and uveal melanomas Heinrich Heimann, Liverpool, United Kingdom 15:25–15:40 Treatment of conjunctival and uveal melanomas Nikolaos Bechrakis, Essen, Germany
14:45–15:45	M2	FREE COMMUNICATION I CHAIRS: Teresa Amaral, Tuebingen, Germany Jürgen Becker, Essen, Germany
15:45–16:15		Break

16:15–17:45	Trianti Hall	<p>SYMPOSIUM SY19 Artificial Intelligence (AI) in dermatology-oncology</p> <p>CHAIRS: Julia Winkler, Heidelberg, Germany Allan C. Halpern, New York, USA Konstantinos Liopyris, Athens, Greece</p> <p>16:15–16:27 Introduction to the current and evolving trends on AI Harald Kittler, Vienna, Austria</p> <p>16:30–16:42 Current state of imaging in dermatology-oncology Allan C. Halpern, New York, USA</p> <p>16:45–16:57 Current state of commercialization and implementation of AI in dermatology-oncology Josep Malvehy, Barcelona, Spain</p> <p>17:00–17:12 Medicolegal and privacy issues on the use of AI Peter Soyer, Brisbane, Australia</p> <p>17:15–17:27 Limitations on the use of AI in dermatology-oncology Konstantinos Liopyris, Athens, Greece</p> <p>17:30–17:42 Opportunities and challenges of AI in dermatology-oncology Julia Winkler, Heidelberg, Germany</p>
16:15–17:45	Banqueting Hall	<p>SYMPOSIUM SY20 Registries for real world treatment data and outcome research</p> <p>CHAIRS: Michael Weichenthal, Kiel, Germany Ana-Maria Forsea, Bucharest, Romania Peter Mohr, Buxtehude, Germany</p> <p>16:15–16:27 Cancer registries – why are they important for skin cancer control Ana-Maria Forsea, Bucharest, Romania</p> <p>16:30–16:42 Where big data fails – a critical view on real-world outcome research Michael Weichenthal, Kiel, Germany</p> <p>16:45–16:57 Systemic therapy in locally advanced basal cell carcinoma and impact of the EADO classification Eve Maubec, Bobigny, France</p> <p>17:00–17:12 Adjuvant therapy in melanoma: new insights from real life data Peter Mohr, Buxtehude, Germany</p> <p>17:15–17:27 Immune related side effects beyond clinical trials using registry data Karijn Suijkerbuijk, Utrecht, The Netherlands</p> <p>17:30–17:42 The role of BRAF + MEK-inhibitors in clinical practice 2025 Inge Marie Svane, Copenhagen, Denmark</p>

16:15-17:45	Mitropoulos Hall	<p>SATELLITE SYMPOSIUM SAT06 Further Sponsor</p> <p>Detailed Information Page 70-76</p>
16:15-17:45	Skalkotas Hall	<p>SYMPOSIUM SY21 Memorial Symposium for Jeff Weber Drug resistance to immune checkpoint inhibition</p> <p>CHAIRS: Thomas Gajewski, Chicago, USA Grant McArthur, Melbourne, Australia Olivier Michielin, Geneva, Switzerland</p> <p>16:15-16:30 Jeff Weber – A life dedicated to melanoma research Thomas Gajewski, Chicago, USA</p> <p>16:30-16:50 Cross resistance between targeted therapies and immune checkpoint inhibition Grant McArthur, Melbourne, Australia</p> <p>16:55-17:15 Systemic therapies to treat PD-1 resistance Olivier Michielin, Geneva, Switzerland</p> <p>17:20-17:40 Understanding mechanisms of immunotherapy response versus resistance through the tumor microenvironment Thomas Gajewski, Chicago, USA</p>

16:15–17:45	M3	<p>SYMPOSIUM SY22 Skin Care in Organ Transplant Patients Europe (SCOPE)</p> <p>CHAIRS: Catherine Harwood, London, United Kingdom Ulrike Leiter-Stöppke, Tuebingen, Germany Alexandra Geusau, Vienna, Austria</p> <p>16:15–16:20 Welcome and introduction Alexandra Geusau, Vienna, Austria</p> <p>16:20–16:32 How to set up a specialty clinic for the dermatologic care of solid-organ transplant recipients – the British Experience Charlotte Proby, Dundee, United Kingdom</p> <p>16:35–16:47 Prevention of NMSC in organ transplant recipients Alexandra Geusau, Vienna, Austria</p> <p>16:50–17:05 The ‘SCOPE-ITSCC metastases study’: Transcriptome-based tumor stratification to better identify cutaneous squamous cell carcinomas at risk for metastases in organ transplant recipients Chrysalyne Schmults, Boston, USA</p> <p>17:10–17:20 Frequently asked, difficult to answer – How to proceed with transplantation post melanoma? Carla Ferrandiz-Pulido, Barcelona, Spain</p> <p>17:20–17:30 Frequently asked, difficult to answer – How to proceed with transplantation post SCC? Ulrike Leiter-Stöppke, Tuebingen, Germany</p> <p>17:30–17:40 Frequently asked, difficult to answer – How to proceed with transplantation post rare skin cancer? Catherine Harwood, London, United Kingdom</p> <p>17:40–17:45 Closing remarks Alexandra Geusau, Vienna, Austria Ulrike Leiter-Stöppke, Tuebingen, Germany Catherine Harwood, London, United Kingdom</p>
16:15–17:45	M2	<p>FREE COMMUNICATION II</p> <p>CHAIRS: Dimitris Bafaloukos, Athens, Greece Jessica Hassel, Heidelberg, Germany</p>
18:00–20:00		Welcome Reception

SCIENTIFIC PROGRAM

FRIDAY, APRIL 4TH, 2025

07:30–08:15	Mitropoulos Hall	<p>SOCRATES´ DIALOGUES I: AN INTERACTIVE MORNING SESSION The role of microbiome for immunotherapies</p> <p>MODERATOR: Thomas Gajewski, Chicago, USA</p>
07:30–08:15	Skalkotas Hall	<p>SOCRATES´ DIALOGUES II: AN INTERACTIVE MORNING SESSION Treatment refractory stage IV melanomas: what do I do?</p> <p>MODERATOR: Teresa Petrella, Toronto, Canada</p>
07:30–08:15	M3	<p>SOCRATES´ DIALOGUES III: AN INTERACTIVE MORNING SESSION Women in dermato-oncology</p> <p>MODERATOR: Carola Berking, Erlangen, Germany</p>
08:15–08:30	Break	
08:30–09:30	Trianti Hall	<p>SYMPOSIUM SY23 Melanoma research</p> <p>CHAIRS: Liz Patton, Edinburgh, United Kingdom Dirk Schadendorf, Essen, Germany</p> <p>08:30–08:42 Novel insights from disease models in melanoma Liz Patton, Edinburgh, United Kingdom</p> <p>08:45–08:57 Metabolic vulnerabilities in melanoma Alpaslan Tasdogan, Essen, Germany</p> <p>09:00–09:12 Tertiary lymphoid structures in melanoma Göran Jönsson, Lund, Sweden</p> <p>09:15–09:27 Mitochondria oncogenetics in melanoma Payam Gammage, Glasgow, Scotland</p>

08:30–09:30	Banqueting Hall	<p>SYMPOSIUM SY24 Congenital nevi: risk and management</p> <p>CHAIRS: Veronica Kinsler, London, United Kingdom Luc Thomas, Lyon, France</p> <p>08:30–08:50 A mouse model of NRAS-driven congenital melanocytic nevus. David Fisher, Cambridge, USA</p> <p>08:50–09:10 Congenital-type nevus of the nail unit, clinical presentation, prognosis and management Luc Thomas, Lyon, France</p> <p>09:10–09:30 RNA therapy for congenital melanocytic naevi Veronica Kinsler, London, United Kingdom</p>
08:30–09:30	Mitropoulos Hall	<p>SATELLITE SYMPOSIUM SAT07 Silver Sponsor</p> <p>Detailed Information Page 70–76</p>
08:30–09:30	Skalkotas Hall	<p>SYMPOSIUM SY25 Management of mucosal melanoma</p> <p>CHAIRS: Paul Lorigan, Manchester, United Kingdom Jun Guo, Beijing, China</p> <p>08:30–08:42 Neoadjuvant and adjuvant therapies for mucosal melanoma Bin Lian, Beijing, China</p> <p>08:45–08:57 Clinical guidelines for the management of mucosal melanoma Paul Lorigan, Manchester, United Kingdom</p> <p>09:00–09:12 Treatment options and challenges in advanced mucosal melanoma Jun Guo, Beijing, China</p> <p>09:15–09:27 Case discussion – Case discussions on the management of anorectal and sinunasal melanomas Paul Nathan, London, United Kingdom</p>

08:30–09:30	M3	<p>SYMPOSIUM SY26 Microbiome in cancer: more than gut feelings?</p> <p>CHAIRS: Jennifer Wargo, Houston, USA Laurence Zitvogel, Paris, France Thomas Gajewski, Chicago, USA</p> <p>08:30–08:45 Targeting the microbiome to promote health and end cancer Jennifer Wargo, Houston, USA</p> <p>08:50–09:05 Intestinal biomarkers in cancer immunosurveillance Laurence Zitvogel, Paris, France</p> <p>09:10–09:25 Mechanisms of regulation of anti-tumor immunity via the commensal microbiota Thomas Gajewski, Chicago, USA</p>
08:30–10:30	M2	<p>FREE COMMUNICATIONS III</p> <p>CHAIRS: Thomas Dirschka, Wuppertal, Germany Helen Gogas, Athens, Greece</p>
09:30–10:30	Triantif Hall	<p>SYMPOSIUM SY27 Controversies – Is there a future for sentinel node biopsy?</p> <p>CHAIRS: Alberto Wainstein, Belo Horizonte, Brazil Piotr Rutkowski, Warsaw, Poland</p> <p>Yes: Vernon Sondak, Tampa, USA No: Alexander van Akkooi, Sydney, Australia</p>
09:30–10:30	Banqueting Hall	<p>SATELLITE SYMPOSIUM SAT08 Gold Sponsor</p> <p>Detailed Information Page 70–76</p>
09:30–10:30	Mitropoulos Hall	<p>SYMPOSIUM SY28 Drug resistance to targeted therapies</p> <p>CHAIRS: Bart Neyns, Brussels, Belgium Olivier Michielin, Geneva, Switzerland</p> <p>09:30–09:42 Introduction to resistance mechanisms Olivier Michilien, Geneva, Switzerland</p> <p>09:45–09:57 Preclinical insight in the molecular basis of response and resistance to targeted therapy in melanoma Poulikos Poulidakos, New York, USA</p> <p>10:00–10:12 Mechanisms of acquired resistance to targeted therapy in melanoma Roger Lo, Los Angeles, USA</p> <p>10:15–10:30 Clinical avenues to overcome resistance to targeted therapy in melanoma Bart Neyns, Brussels, Belgium</p>

09:30–10:30	Skalkotas Hall	<p>SYMPOSIUM SY29 Molecular tumor board for skin cancers</p> <p>CHAIRS: Teresa Amaral, Tuebingen, Germany Ryan Sullivan, Boston, USA Richard Scolyer, Sydney, Australia</p> <p>09:30–09:45 Case 1: Novel therapies for BRAF and neuroblastoma RAS viral oncogene homolog mutant melanoma Teresa Amaral, Tuebingen, Germany</p> <p>09:50–10:05 Case 2: Molecular targeting of other genetic alterations – including epidermal growth factor receptor (EGFR), neurotrophic tyrosine receptor kinase (NTRK), KIT, and tumor mutational burden (TMB) Ryan Sullivan, Boston, USA</p> <p>10:10–10:25 Case 3: Personalised immunotherapy platform for advanced stage melanoma patients Richard Scolyer, Sydney, Australia</p>
09:30–10:30	M3	<p>SYMPOSIUM SY30 Treatment of field cancerization including actinic cheilitis</p> <p>CHAIRS: Nicole Kelleners-Smeets, Maastricht, The Netherlands Maria Concetta Fargnoli, Rome, Italy Markus Heppt, Erlangen, Germany</p> <p>09:30–09:45 Hot of the press – what's new in the treatment of actinic keratosis and field cancerization? Markus Heppt, Erlangen, Germany</p> <p>09:50–10:05 Therapeutic options for actinic cheilitis Maria Concetta Fargnoli, Rome, Italy</p> <p>10:10–10:25 Treatment of actinic keratosis from patients' perspective Nicole Kelleners-Smeets, Maastricht, The Netherlands</p>
10:30–11:00	Break	
11:00–12:00	Trianti Hall	<p>SYMPOSIUM SY31 Adjuvant treatment of melanoma</p> <p>CHAIRS: Sanjiv Agarwala, Philadelphia, USA Hussein Tawbi, Houston, USA Axel Hauschild, Kiel, Germany</p> <p>11:00–11:12 Setting the stage: current adjuvant treatment modalities Sanjiv Agarwala, Philadelphia, USA</p> <p>11:15–11:27 Adjuvant and which strategy (IO vs targeted) in the light of neoadjuvant breakthroughs Mario Mandala, Perugia, Italy</p> <p>11:30–11:42 Should we treat lower risk patients (stage IB/IIA/IIB) Axel Hauschild, Kiel, Germany</p> <p>11:45–11:57 Innovative treatment strategies: What comes next? Hussein Tawbi, Houston, USA</p>

11:00–12:00	Banqueting Hall	<p>SYMPOSIUM SY32 Management of brain metastases</p> <p>CHAIRS: Michael Davies, Houston, USA Helen Gogas, Athens, Greece Omid Hamid, Los Angeles, USA</p> <p>11:00–11:12 Update on immune checkpoint inhibitors for melanoma brain metastases Helen Gogas, Athens, Greece</p> <p>11:15–11:27 Targeted therapy for and molecular biology of melanoma brain metastases Michael Davies, Houston, USA</p> <p>11:30–11:42 New approaches from LMD and brain metastases from melanoma Omid Hamid, Los Angeles, USA</p> <p>11:45–11:57 Brain metastases – The value of interdisciplinary management Friedegund Meier, Dresden, Germany</p>
11:00–12:00	Mitropoulos Hall	<p>SATELLITE SYMPOSIUM SAT09 Further Sponsor</p> <p>Detailed Information Page 70–76</p>
11:00–12:00	Skalkotas Hall	<p>SYMPOSIUM SY33 Radiotherapy for melanoma and other skin cancers: where are we now? (ESTRO)</p> <p>CHAIRS: Luca Tagliaferri, Rome, Italy Reinhard Dummer, Zurich, Switzerland</p> <p>11:00–11:12 Grenz Ray and soft-XRay therapy from a dermatological perspective Reinhard Dummer, Zurich, Switzerland</p> <p>11:15–11:27 Value-based medicine: “personalized patient centric approach” and integrated therapies in non-melanoma skin cancer Luca Tagliaferri, Rome, Italy</p> <p>11:30–11:42 Advances in External Beam Radiotherapy (EBRT) for the management of NMSC and melanoma: what we need to know Agata Rembielak, Manchester, United Kingdom</p> <p>11:45–11:57 Advances in Interventional Radiotherapy (brachytherapy) for the management of NMSC and melanoma: what we need to know Piotr Wojcieszek, Gliwice, Poland</p>

11:00–12:00	M3	<p>SYMPOSIUM SY34 Surgical pearls in the treatment of skin cancer</p> <p>CHAIRS: Ricardo Vieira, Coimbra, Portugal Roland Kaufmann, Frankfurt, Germany</p> <p>11:00–11:09 All-time tips and tricks Roland Kaufmann, Frankfurt, Germany</p> <p>11:12–11:21 My pearls around the mouth Elena Rossi, Modena, Italy</p> <p>11:24–11:33 Surgical pearls in periocular cancer excisions Ricardo Vieira, Coimbra, Portugal</p> <p>11:36–11:45 My pearls around the cheek and temple Myrto Trakatelli, Thessaloniki, Greece</p> <p>11:48–11:57 My pearls in repairs of the nose David Moreno, Seville, Spain</p>
11:00–12:00	M2	<p>SYMPOSIUM SY35 Rare Tumors (adnexal, sebaceous, dermatofibrosarcoma protuberans)</p> <p>CHAIR: Philippe Saiag, Paris, France David Adams, Cambridge, United Kingdom</p> <p>11:00–11:15 The genomic landscape of rare adnexal tumours: The Dermatlas Project David Adams, Cambridge, United Kingdom</p> <p>11:20–11:35 Recent clinical advances in adnexal tumors Thomas Jouary, Bordeaux, France</p> <p>11:40–11:55 Dermatofibrosarcoma protuberans: update of the EADO-EORTC guideline Philippe Saiag, Paris, France</p>
12:00–13:00	Trianti Hall	<p>SATELLITE SYMPOSIUM SAT10 Platinum Sponsor</p> <p>Detailed Information Page 70–76</p>
13:00–14:00	Break	
14:00–14:30	Trianti Hall	<p>KEYNOTE LECTURE KEY03 CHAIR: Christopher Höller, Vienna, Austria</p> <p>Diagnostic tools for skin cancer detection beyond dermoscopy Josep Malvehy, Barcelona, Spain</p>

14:30–15:00	Trianti Hall	<p>KEYNOTE LECTURE KEY04 CHAIR: Jeffrey Gershenwald, Houston, USA</p> <p>New diagnostics, prognostic biomarkers and systemic therapy strategies sharply reduce the need for surgery in melanoma Alexander Eggermont, Utrecht, The Netherlands</p>
15:00–16:00	Trianti Hall	<p>SATELLITE SYMPOSIUM SAT11 Platinum Sponsor</p> <p>Detailed Information Page 70–76</p>
16:00–16:30	Break	
16:30–17:30	Trianti Hall	<p>SYMPOSIUM SY36 Immune checkpoint inhibition for non-melanoma skin cancer</p> <p>CHAIRS: Paolo Ascierto, Naples, Italy Dirk Schadendorf, Essen, Germany</p> <p>16:30–16:45 Basal cell carcinoma: strategies to treat in 2025 Dirk Schadendorf, Essen, Germany</p> <p>16:50–17:05 Cutaneous squamous cell carcinoma – Treatment options in adjuvant, neoadjuvant and palliative setting Paolo Ascierto, Naples, Italy</p> <p>17:10–17:25 Merkel cell carcinoma – guideline update and more Iwona Lugowska, Warsaw, Poland</p>
16:30–17:30	Banqueting Hall	<p>SYMPOSIUM SY37 High-risk melanocytic nevi: are they existing, and how to define what to do?</p> <p>CHAIRS: Veronique Bataille, London, United Kingdom Giuseppe Argenziano, Naples, Italy</p> <p>16:30–16:45 Melanocytic naevi from a biological and evolutionary perspective Veronique Bataille, London, United Kingdom</p> <p>16:50–17:05 High-risk melanocytic nevi: definition from a clinical perspective Giuseppe Argenziano, Naples, Italy</p> <p>17:10–17:25 High-risk melanocytic nevi: definition from a histopathologic perspective Harald Kittler, Vienna, Austria</p>
16:30–17:30	Mitropoulos Hall	<p>SATELLITE SYMPOSIUM SAT12 Further Sponsor</p> <p>Detailed Information Page 70–76</p>

16:30–17:30	Sikalokotas Hall	<p>SYMPOSIUM SY38 Drug access across the world: approval is not reimbursement!</p> <p>CHAIRS: Lidija Kandolf, Belgrade, Serbia Paul Lorigan, Manchester, United Kingdom</p> <p>16:30–16:45 Access to skin cancer medications in Europe Lidija Kandolf, Belgrade, Serbia</p> <p>16:50–17:05 Access to skin cancer medications in Latin America Rodrigo Munhoz, Sao Paulo, Brazil</p> <p>17:10–17:25 The role of academia, industry and regulatory agencies in developing practice-defining trials Paul Lorigan, Manchester, United Kingdom</p>
16:30–17:30	M3	<p>SYMPOSIUM SY39 Cutaneous sarcomas: diagnosis and treatment</p> <p>CHAIRS: Stephan Grabbe, Mainz, Germany Rodrigo Munhoz, Sao Paulo, Brazil</p> <p>17:30–17:42 Key questions about cutaneous sarcomas Stephan Grabbe, Mainz, Germany</p> <p>17:45–17:57 Dermatofibrosarcoma protuberans Philippe Saiag, Paris, France</p> <p>18:00–18:12 Pleomorphic Dermal Sarcoma & Atypical Fibroxanthoma Rodrigo Munhoz, Sao Paulo, Brazil</p> <p>18:15–18:27 Angiosarcoma/Kaposi's sarcoma Celéste Lebbé, Paris, France</p>
16:30–17:30	M2	<p>SYMPOSIUM SY40 Moh's micrographic surgery and skin cancer management</p> <p>CHAIRS: Joseph Alcalay, Tel-Aviv, Israel Sotirios Theoxaris, Athens, Greece</p> <p>16:00–16:15 Mohs vs Slow Mohs: Pros and cons Roland Kaufmann, Frankfurt, Germany</p> <p>16:20–16:35 Pitfalls in Mohs surgery Ricardo Vieira, Coimbra, Portugal</p> <p>16:40–16:55 Beyond the scalpel – when Mohs surgery is not enough Joseph Alcalay, Tel-Aviv, Israel</p>

17:30–18:30	Triantif Hall	<p>SYMPOSIUM SY41 Global epidemiologic trends and survival in skin cancer</p> <p>CHAIRS: Zoe Venables, Norwich, United Kingdom David Whiteman, Brisbane, Australia</p> <p>17:30–17:42 Global Melanoma Trends: Insights from Swedish Data and Projections for the Future Hildur Helgadóttir, Stockholm, Sweden</p> <p>17:45–17:57 Trends in melanoma incidence in Australia by age and ancestry: public health impact or population admixture? David Whiteman, Brisbane, Australia</p> <p>18:00–18:12 Long-term survival and causes of death across Breslow thickness categories Anne Cust, Sydney, Australia</p> <p>18:15–18:27 Shifting skin cancer patterns in England: incidence and mortality trends over the past 20 years Zoe Venables, Norwich, United Kingdom</p>
17:30–18:30	Banqueting Hall	<p>SYMPOSIUM SY42 Metastatic uveal melanoma – current and emerging treatment options</p> <p>CHAIRS: Paul Nathan, London, United Kingdom Jessica Hassel, Heidelberg, Germany Heather Shaw, London, United Kingdom</p> <p>17:30–17:45 First-line immunotherapy of metastatic uveal melanoma Jessica Hassel, Heidelberg, Germany</p> <p>17:50–18:05 Adjuvant treatment of high risk uveal melanoma Paul Nathan, London, United Kingdom</p> <p>18:10–18:25 New targets and approaches in development Heather Shaw, London, United Kingdom</p>
17:30–18:30	Mitropoulos Hall	<p>SATELLITE SYMPOSIUM SAT13 Further Sponsor</p> <p>Detailed Information Page 70–76</p>

17:30–19:00	Skalkotas Hall	<p>SYMPOSIUM SY43 Occupational skin cancer: The sleeping giant (4th Multi-stakeholder summit)</p> <p>MODERATORS: Swen-Malte John, Osnabrueck, Germany Myrto Trakatelli, Thessaloniki, Greece</p> <p>17:30–17:45 Welcoming remarks and Introduction to Summit</p> <p>17:33–17:36 The Stakeholder Summit Journey Swen Malte John, Osnabrueck, Germany</p> <p>17:36–17:39 EADO Josep Malveyh, Barcelona, Spain</p> <p>17:39–17:42 GlobalSkin Jennifer Austin</p> <p>17:42–17:45 EADV TBA</p> <p>17:45–18:25 Prevention and acknowledgement of occupational skin cancer (Short intros)</p> <p>17:45–17:51 World Health Organisations (WHO) perspectives Emilie van Deventer</p> <p>17:51–17:57 Skin cancer as an occupational disease – the ILO perspective Shengli Niu</p> <p>17:57–18:03 Economic perspective of skin cancer prevention and registries Matthias Augustin, Hamburg, Germany</p> <p>18:03–18:09 The Australian experience with skin cancer prevention David Whiteman, Brisbane, Australia</p> <p>18:09–18:13 Representative Greek ministry of Health</p> <p>18:13–18:17 Representative Greek ministry of Labour</p> <p>18:17–18:21 EU-representative DG Sante</p> <p>18:21–18:25 EU-representative DG Employment</p> <p>18:25–18:55 Panel Discussion all speakers</p> <p>18:55–19:00 Wrap up and Global Call to Action Myrto Trakatelli, Thessaloniki, Greece</p>
17:30–18:30	M3	<p>SYMPOSIUM SY44 Skin cancer on colored skin: clinical appearance and treatment</p> <p>CHAIRS: Dagmar Whitaker, Cape Town, South Africa Aleksandar Sekulic, Phoenix, USA</p> <p>17:30–17:42 Skin cancer in dark skin – a bigger problem than we think? Dagmar Whitaker, Cape Town South Africa</p> <p>17:45–17:57 Challenges of skin cancer in the Asian population Hisashi Uhara, Sapporo, Japan</p> <p>18:00–18:12 Melanoma in dark skin – how can we increase awareness and achieve better disease outcomes? Willie Visser, Stellenbosch, South Africa</p> <p>18:15–18:27 Treatment innovations and pipeline products for AK Aleksandar Sekulic, Phoenix, USA</p>

SCIENTIFIC PROGRAM

SATURDAY, APRIL 5TH, 2025

07:30–08:15	Mitropoulos Hall	<p>SOCRATES´ DIALOGUES IV: AN INTERACTIVE MORNING SESSION How to build up a career in dermato-oncology?</p> <p>MODERATOR: Alexander Stratigos, Athens, Greece</p>
07:30–08:15	Skalkotas Hall	<p>SOCRATES´ DIALOGUES V: AN INTERACTIVE MORNING SESSION Prognostic and predictive biomarkers for melanoma</p> <p>MODERATOR: Reinhard Dummer, Zurich, Switzerland</p>
07:30–08:15	M3	<p>SOCRATES´ DIALOGUES VI: AN INTERACTIVE MORNING SESSION Challenges in neoadjuvant therapy</p> <p>MODERATOR: Sapna Patel, Denver, USA</p>
08:15–08:30	Break	
08:30–09:00	Trianti Hall	<p>KEYNOTE LECTURE KEY05 CHAIR: Helen Gogas, Athens, Greece</p> <p>Neoadjuvant therapy: a new standard of care for melanomas? Georgina Long, Sydney, Australia</p>
09:00–10:00	Trianti Hall	<p>SYMPOSIUM SY45 Primary prevention of skin cancer</p> <p>CHAIRS: Veronique del Marmol, Brussels, Belgium Mirna Situm, Zagreb, Croatia</p> <p>09:00–09:12 Is primary prevention effective at all? David Whiteman, Brisbane, Australia</p> <p>09:15–09:27 Systemic chemoprevention: a holy grail? Peter Soyer, Brisbane, Australia</p> <p>09:30–09:42 Sunscreen: friend or foe? Veronique del Marmol, Brussels, Belgium</p> <p>09:45–09:57 23 years of skin cancer prevention campaigns in Croatia Mirna Situm, Zagreb, Croatia</p>

09:00–10:00	Banqueting Hall	<p>SYMPOSIUM SY46 Is there a future for sentinel node biopsy?</p> <p>CHAIRS: Alexander van Akkooi, Sydney, Australia Merrick I. Ross, Houston, USA</p> <p>09:00–09:15 Sentinel lymph node dissection (SLND) in cutaneous squamous cell carcinoma Merrick I. Ross, Houston, Texas</p> <p>09:20–09:35 SLND in Merkel cell carcinoma Alexander van Akkooi, Sydney, Australia</p> <p>09:40–09:55 SLND in melanoma Piotr Rutkowski, Warsaw, Poland</p>
09:00–10:00	Mitropoulos Hall	<p>SATELLITE SYMPOSIUM SAT14 Further Sponsor</p> <p>Detailed Information Page 70–76</p>
09:00–10:00	Sikalkotas Hall	<p>SYMPOSIUM SY47 Patient Advocacy Groups</p> <p>CHAIRS: Bettina Ryll, Uppsala, Sweden</p> <p>09:00–09:05 Welcome and Introduction Bettina Ryll, Uppsala, Sweden</p> <p>09:05–09:15 Long-term follow-up of Stage 3 Melanoma patients in Germany Katharina Kaminski, Essen, Germany</p> <p>09:15–09:25 Addressing gaps in melanoma care: Leveraging biomarkers for equity and better outcomes Samantha Guild, Richmond, USA</p> <p>09:25–09:35 Access to novel medicines – the WHO Europe Novel Medicines Platform Violeta Astratinei, Amsterdam, The Netherlands</p> <p>09:35–09:45 Access to advanced molecular testing for additional treatment options in Melanoma – learnings from DRUP-like clinical trials Bettina Ryll, Uppsala, Sweden</p> <p>09:45–10:00 Questions and discussions</p>

09:00–10:00	M3	<p>SYMPOSIUM SY48 Interdisciplinary tumor board: challenging skin cancer cases II</p> <p>CHAIRS: Petr Arenberger, Prague, Czech Republic Matilda Bylaite-Bucinskiene, Vilnius, Lithuania David Moreno-Ramirez, Seville, Spain</p> <p>09:00–09:10 Case 1 Petr Arenberger, Prague, Czech Republic</p> <p>09:12–09:22 Case 2 David Moreno-Ramirez, Seville, Spain</p> <p>09:24–09:34 Case 3 Monika Arenbergerova, Prague, Czech Republic</p> <p>09:36–09:46 Case 4 Mirna Situm, Zagreb, Croatia</p> <p>09:46–09:58 Case 5 Matilda Bylaite-Bucinskiene, Vilnius, Lithuania</p>
10:00–10:30	Break	
10:30–11:00	Trianti Hall	<p>KEYNOTE LECTURE KEY06 CHAIR: Ryan Sullivan, Boston, USA</p> <p>Improving outcomes in melanoma beyond the standard use of immune checkpoint blockers Caroline Robert, Paris, France</p>
11:00–11:30	Trianti Hall	<p>KEYNOTE LECTURE KEY07 CHAIR: Brigitte Dréno, Nantes, France</p> <p>The future of non-melanoma skin cancer treatment Chrysalynne Schmults, Boston, USA</p>
11:00–12:30	M2	<p>FREE COMMUNICATION IV</p> <p>CHAIRS: Lidija Kandolf, Belgrade, Serbia Konstantinos Krasagakis, Athens, Greece</p>

11:30-12:30	Tiranti Hall	<p>SYMPOSIUM SY49 New devices for...</p> <p>CHAIRS: Giovanni Pellacani, Modena, Italy Julia Welzel, Augsburg, Germany</p> <p>11:30-11:42 ... Pigmented lesions Giovanni Pellacani, Rome, Italy</p> <p>11:45-11:57 ... Epithelial tumors Mariano Suppa, Brussels, Belgium</p> <p>12:00-12:12 ... Mohs´ surgery with ex vivo confocal microscopy Javiera Perez, Barcelona, Spain</p> <p>12:15-12:27 ... AI in imaging Julia Welzel, Augsburg, Germany</p>
11:30-12:30	Banqueting Hall	<p>SYMPOSIUM SY50 Management of adverse events in immuno-oncology</p> <p>CHAIRS: Brigitte Dréno, Nantes, France Elisabeth Livingstone, Essen, Germany</p> <p>11:30-11:42 Immune-related cardiotoxicity: how to detect, monitor and treat? Carrie Lenneman, Birmingham, USA</p> <p>11:45-11:57 Difficult to treat colitis: what's next? Elisabeth Livingstone, Essen, Germany</p> <p>12:00-12:12 Balancing ir-adverse events and benefit of immunotherapy Brigitte Dréno, Nantes, France</p> <p>12:15-12:27 Get ready for bispecific antibodies and T cells: how to prevent and treat specific advers events Heather Shaw, London, United Kingdom</p>
11:30-12:30	Mitropoulos Hall	<p>SATELLITE SYMPOSIUM SAT15 Further Sponsor</p> <p>Detailed Information Page 70-76</p>

11:30-12:30	Sikalkotas Hall	<p>SYMPOSIUM SY51 Promising agents for PD1-refractory patients</p> <p>CHAIRS: Michael Postow, New York, USA Ana Arance, Barcelona, Spain</p> <p>11:30-11:42 Efficacy and safety of RP1 combined with nivolumab in patients with anti-PD-1-failed melanoma from the IGNYTE clinical trial Michael K. Wong, Houston, USA</p> <p>11:45-11:57 Bispecific antibody therapies: Emerging new strategies and learnings from tebentafusp Jessica Hassel, Heidelberg, Germany</p> <p>12:00-12:12 Can Histone deacetylases (HDAC) inhibitors challenge immune checkpoint resistance in melanoma? Ana Arance, Barcelona, Spain</p> <p>12:15-12:27 Will antibody drug conjugates have a role in melanoma treatment? Michael Postow, New York, USA</p>
11:30-12:30	M3	<p>SYMPOSIUM SY52 Melanoma – genomics and morphology</p> <p>CHAIRS: Sarah Coupland, Liverpool, United Kingdom David Adams, Cambridge, United Kingdom</p> <p>11:30-11:42 Translating the genomic architecture and pathology of melanoma into new therapies David Adams, Cambridge, United Kingdom</p> <p>11:45-11:57 The spatial transcriptomics of leptomeningeal spread in melanoma Inna Smalley, Tampa, USA</p> <p>12:00-12:12 Classification of the tumour microenvironment and immune therapy response James Wilmott, Sydney, Australia</p> <p>12:15-12:27 Vascular lakes and outcome in uveal melanoma Sarah Coupland, Liverpool, United Kingdom</p>
12:30-12:40		<p>POSTER AWARDS Committee: Céleste Lebbé, Paris, France Chrysalynne Schmults, Boston, USA Friedegund Meier, Dresden, Germany Jürgen Becker, Essen, Germany</p>
12:40-13:15		<p>BREAK</p>

13:15-14:15	Trianti Hall	<p>SYMPOSIUM SY53 Treatment at the end of the life</p> <p>CHAIRS: Andrea Forschner, Tuebingen, Germany Carola Berking, Erlangen, Germany Sapna Patel, Denver, USA</p> <p>13:15-13:30 End-of-life therapy of advanced skin cancer: Results of a large multiregistry study Andrea Forschner, Tuebingen, Germany</p> <p>13:35-13:50 Challenges and evidence-based guidelines of palliative care in Germany Carola Berking, Erlangen, Germany</p> <p>13:55-14:10 Treatment beyond progression in skin cancer Sapna Patel, Denver, USA</p>
13:15-14:15	Banqueting Hall	<p>SYMPOSIUM SY54 Management of adverse events in targeted therapies</p> <p>CHAIRS: Vincent Sibaud, Toulouse, France Viky Nikolaou, Athens, Greece</p> <p>13:15-13:27 New insights in epidermal growth factors receptor-related dermatologic toxicities Michela Starrace, Bologna, Italy</p> <p>13:30-13:42 Management of systemic adverse events of targeted therapies Peter Kölblinger, Salzburg, Austria</p> <p>13:45-13:57 Management of adverse events caused by hedgehog inhibitors Viky Nikolaou, Athens, Greece</p> <p>14:00-14:12 New targeted therapies: new dermatological toxicities Vincent Sibaud, Toulouse, France</p>
13:15-14:15	Mitropoulos Hall	<p>SYMPOSIUM SY55 Management of lentigo maligna and acral lentiginous melanomas</p> <p>CHAIRS: Zoe Apalla, Thessaloniki, Greece Yasuhiro Nakamura, Saitama, Japan</p> <p>13:15-13:27 Surgical management of lentigo maligna Eduardo Nagore, Valencia, Spain</p> <p>13:30-13:42 The role of topical immunotherapy in the management of lentigo maligna Zoe Apalla, Thessaloniki, Greece</p> <p>13:45-13:57 Surgical management for acral melanoma: different from non-acral cutaneous melanomas? Takamichi Ito, Fukuoka, Japan</p> <p>14:00-14:12 Adjuvant immunotherapy of acral melanoma – as good as for other subtypes? Yasuhiro Nakamura, Saotama, Japan</p>

13:15-14:15	Skalkotas Hall	<p>SYMPOSIUM SY56 Immune checkpoint inhibition in immunocompromised patients</p> <p>CHAIRS: Lisa Zimmer, Essen, Germany Elsemieke Plasmeijer, Amsterdam, The Netherlands</p> <p>13:15-13:30 Immune checkpoint inhibition in patients with hematological malignancy Florentia Dimitriou, Houston, USA</p> <p>13:35-13:50 Immune checkpoint inhibition in organ transplant patients Lisa Zimmer, Essen, Germany</p> <p>13:55-14:10 Upcoming research on local immunotherapy Elsemieke Plasmeijer, Amsterdam, The Netherlands</p>
13:15-14:15	M3	<p>SYMPOSIUM SY57 Melanocytic lesions of unknown potential: biology, prognosis, treatment and follow-up</p> <p>CHAIRS: Klaus Griewank, Essen, Germany Francesca Maria Bosisio, Leuven, Belgium</p> <p>13:15-13:30 Introduction to the concept of atypical melanocytic tumors: a practical approach Francesca Maria Bosisio, Leuven, Belgium</p> <p>13:35-13:50 Latest in genetics in difficult to classify tumors Hensin Tsao, Boston, USA</p> <p>13:55-14:10 AI in classifying MELTUMP - Experience so far and potential Klaus Griewank, Essen, Germany</p>

13:15-14:45	M2	<p>SYMPOSIUM SY58 Cutaneous melanoma risk and progression in Mediterranean populations and beyond (MelaNostrum)</p> <p>CHAIR: Maria Teresa Landi, Bethesda, USA</p> <p>13:15-13:20: Introduction to the MelaNostrum Consortium Maria Teresa Landi, Bethesda, USA</p> <p>13:20-13:35: Novel susceptibility variants in >3000 familial melanoma cases from Mediterranean countries Kevin Brown, Bethesda, USA</p> <p>13:35-13:50: Characterization of melanomas in subjects with no common risk factors for the disease Eduardo Nagore, Valencia, Spain</p> <p>13:50-14:06: A genome-wide association study (GWAS) of >76,000 melanoma cases worldwide Maria Teresa Landi, Bethesda, USA</p> <p>14:06-14:14: Spatial multi-omics analysis of progression and immunoediting to evaluate individual recurrence risk prediction in stage II cutaneous melanoma Lucia Di Nardo, Rome, Italy</p> <p>14:14-14:22: Molecular profiling and imaging of paired primary and metastatic melanomas: an ongoing Consortium-based research project Cristina Pellegrini, L'Aquila, Italy</p> <p>14:22-14:30: A multiparameter liquid biopsy approach allows tracking of melanoma dynamics and early detection of treatment resistance Maria Chiara Scaini, Padova, Italy</p> <p>14:30-14:45: Discussion</p>
14:15-15:15	Trianti Hall	<p>SYMPOSIUM SY59 Dermoscopy 2: Dermoscopy in melanoma management</p> <p>CHAIRS: Aimilios Lallas, Thessaloniki, Greece Caterina Longo, Reggio Emilia, Italy</p> <p>14:15-14:27 ... does the age matter? Aimilios Lallas, Thessaloniki, Greece</p> <p>14:30-14:42 ... does anatomic location matter? Caterina Longo, Reggio Emilia, Italy</p> <p>14:45-14:57 ... does size matter? Elvira Moscarella, Reggio Emilia, Italy</p> <p>15:00-15:12 ... does skin color matter? Bengu Nisa Akay, Ankara, Turkey</p>

14:15-15:15	Banqueting Hall	<p>SYMPOSIUM SY60 Actinic keratosis: current treatment and future perspectives</p> <p>CHAIRS: Catherine Harwood, London, United Kingdom Thomas Dirschka, Wuppertal, Germany Aleksandar Sekulic, Phoenix, USA</p> <p>14:15-14:27 Prognostic factors in actinic keratoses Thomas Dirschka, Wuppertal, Germany</p> <p>14:30-14:42 Actinic keratoses in immunosuppressed patients Catherine Harwood, London, United Kingdom</p> <p>14:45-14:57 Modern imaging of actinic skin damage Mariano Suppa, Brussels, Belgium</p> <p>15:00-15:12 Treatment innovations and pipeline products for actinic keratosis Aleksandar Sekulic, Phoenix, USA</p>
14:15-15:15	Mitropoulos Hall	<p>SATELLITE SYMPOSIUM SAT16 Further Sponsor</p> <p>Detailed Information Page 70-76</p>
14:15-15:15	Skalkotas Hall	<p>SYMPOSIUM SY61 Diagnosis and management of cutaneous T-and B-cell lymphomas</p> <p>CHAIRS: Pablo Ortiz, Madrid, Spain Michael Weichenthal, Kiel, Germany</p> <p>14:15-14:27 How I manage mycosis fungoides and Sézary syndrome Pablo Ortiz-Romero, Madrid, Spain</p> <p>14:30-14:42 Itch management in cutaneous T-cell lymphoma Evangelia Papadavid, Athens, Greece</p> <p>14:45-14:57 Diagnosis and management of primary cutaneous B-cell lymphomas Michael Weichenthal, Kiel, Germany</p> <p>15:00-15:12 What is new in diagnosis and management of aggressive T-cell lymphomas Julia Scarisbrick, Birmingham, United Kingdom</p>

14:15-15:15	M3	<p>SYMPOSIUM SY62 Interdisciplinary tumor board: challenging skin cancer cases III</p> <p>CHAIRS: Thomas Eigentler, Berlin, Germany Judit Oláh, Szeged, Hungary</p> <p>14:15-14:25 Leptomeningeal melanomatosis without melanoma Thomas Eigentler, Berlin, Germany</p> <p>14:27-14:37 Local ablative techniques in the complex management of the difficult-to-treat cutaneous tumours Judit Olah, Szeged, Hungary</p> <p>14:39-14:49 Difficult-to-treat epithelial tumours on the head and neck region Rolland Gyulai, Szeged, Hungary</p> <p>14:51-15:01 Skin cancer treatment in pregnancy Marie-Lena Rasch, Tuebingen, Germany</p> <p>15:03-15:13 Against all odds Georg Weinlich, Innsbruck, Austria</p>
15:15-16:15	Trianti Hall	<p>SYMPOSIUM SY63 Dermoscopy 3: Difficult clinical scenarios</p> <p>CHAIRS: Harald Kittler, Vienna, Austria Aimilios Lallas, Thessaloniki, Greece</p> <p>15:15-15:27 Young patients with nodular lesions Aimilios Lallas, Thessaloniki, Greece</p> <p>15:30-15:42 Middle aged patient with melanonychia striata Harald Kittler, Vienna, Austria</p> <p>15:45-15:57 Old patients with flat pigmented lesions Giuseppe Argenziano, Naples, Italy</p> <p>16:00-16:12 Patients with genital lesions Betty Lazaridou, Thessaloniki, Greece</p>

15:15-16:15	Banqueting Hall	<p>SYMPOSIUM SY64 Surgery of stage IV melanoma: still needed?</p> <p>CHAIRS: Alberto Wainstein, Belo Horizonte, Brazil Vernon Sondak, Tampa, USA Piotr Rutkowski, Warsaw, Poland</p> <p>15:15-15:30 When is surgery indicated for stage IV melanoma? Alberto Wainstein, Belo Horizonte, Brazil</p> <p>15:35-15:50 When and what are the adjuvant therapy indications and regimens for stage IV melanoma? Piotr Rutkowski, Warsaw, Poland</p> <p>15:55-16:10 Principles of surgery after systemic therapy Vernon Sondak, Tampa, USA</p>
15:15-16:15	Mitropoulos Hall	<p>SATELLITE SYMPOSIUM SAT17 Further Sponsor</p> <p>Detailed Information Page 70-76</p>
15:15-16:15	Skalkotas Hall	<p>SYMPOSIUM SY65 Current primary staging and follow-up recommendations for melanoma patients</p> <p>CHAIRS: Iris Zalaudek, Trieste, Italy Ulrike Leiter-Stöppke, Tuebingen, Germany</p> <p>15:15-15:30 Primary staging and follow-up in stage I/IIA – less is more? Iris Zalaudek, Trieste, Italy</p> <p>15:35-15:50 Staging and imaging in stage IIB-III before during and after adjuvant therapy Ulrike Leiter-Stöppke, Tuebingen, Germany</p> <p>15:55-16:10 Staging and follow-up in stage IV Michael Weichenthal, Kiel, Germany</p>
15:15-16:15	M3	<p>SYMPOSIUM SY66 Genetic susceptibility of melanoma and cancer syndromes</p> <p>CHAIRS: Susana Puig, Barcelona, Spain Irene Stefanaki, Athens, Greece</p> <p>15:15-15:30 Characterization of genetically enriched melanoma cases in Greece Irene Stefanaki, Athens, Greece</p> <p>15:35-15:50 Genetic susceptibility to melanoma and deep phenotyping Susana Puig, Barcelona, Spain</p> <p>15:55-16:10 Other cancer syndromes with skin cancer Anne Zaremba, Essen, Germany</p>
16:15-16:30		<p>FAREWELL & CLOSING REMARKS Alexander Stratigos, Athens, Greece</p>

SATELLITE SYMPOSIA AT A GLANCE

APRIL 3TH-5TH, 2025

Trianti Hall 1,500 seats/Ground Level	Banqueting Hall 650 seats/Level -2	Mitropoulos Hall 450 seats/Old Building	
	09:15-10:15 SATELLITE SYMPOSIUM SAT01 Gold		THURSDAY, APRIL 3 TH , 2025
11:45-12:45 SATELLITE SYMPOSIUM SAT02 Regeneron			
	13:45-14:45 SATELLITE SYMPOSIUM SAT03 Bristol Meyer Squibb		
		14:45-15:15 SATELLITE SYMPOSIUM SAT04 Silver	
		15:15-15:45 SATELLITE SYMPOSIUM SAT05 Replimune	
		16:15-16:45 SATELLITE SYMPOSIUM SAT06 Almirall	
			FRIDAY, APRIL 4 TH , 2025
		08:30-09:30 SATELLITE SYMPOSIUM SAT07 Pierre Fabre	
	09:30-10:30 SATELLITE SYMPOSIUM SAT08 Immunicore		
12:00-13:00 SATELLITE SYMPOSIUM SAT10 MSD		11:00-12:00 SATELLITE SYMPOSIUM SAT09 SunPharma	
15:00-16:00 SATELLITE SYMPOSIUM SAT11 Regeneron			
		16:30-17:30 SATELLITE SYMPOSIUM SAT12 SunPharma	
		17:30-18:30 SATELLITE SYMPOSIUM SAT13 Further Sponsor	
			SATURDAY, APRIL 5 TH , 2025
		09:00-10:00 SATELLITE SYMPOSIUM SAT14 Further Sponsor	
		11:30-12:30 SATELLITE SYMPOSIUM SAT15 Further Sponsor	
		14:15-15:15 SATELLITE SYMPOSIUM SAT16 SunPharma	
		15:15-16:15 SATELLITE SYMPOSIUM SAT17 Further Sponsor	

SATELLITE SYMPOSIA PROGRAM

THURSDAY, APRIL 3TH, 2025

Banqueting Hall 09:15–10:15

GOLD SPONSOR SATELLITE SYMPOSIUM **SAT01**

To be announced

REGENERON

Trianti Hall 11:45–12:45

PLATINUM SPONSOR SATELLITE SYMPOSIUM **SAT02**

New Horizons: Reshaping the Treatment Landscape of Non-melanoma Skin Cancer

CHAIR: Alexander Stratigos, Athens, Greece

11:45–12:00 **Welcome and Introduction**

Alexander Stratigos, Athens, Greece

12:00–12:15 **Paving the Way: Paradigm Shifts in the Treatment of Non-melanoma Skin Cancer**

Paolo Ascierto, Naples, Italy

12:15–12:30 **Bridging the Gaps: Addressing Unmet Needs in Non-melanoma Skin Cancer (Illustrative Cases)**

Reinhard Dummer, Zurich, Switzerland

12:30–12:45 **Audience Q&A and Faculty Discussion**

All



Banqueting Hall 13:45–14:45

GOLD SPONSOR SATELLITE SYMPOSIUM **SAT03**

**Exploring metastatic melanoma therapies:
The value of the patient's perspective**

To be announced

Mitropoulos Hall 14:45–15:15

SILVER SPONSOR SATELLITE SYMPOSIUM **SAT04**

To be announced



Mitropoulos Hall 15:15–15:45

SILVER SPONSOR SATELLITE SYMPOSIUM **SAT05**

To be announced



Mitropoulos Hall 16:15–16:45

FURTHER SPONSOR SATELLITE SYMPOSIUM **SAT06**

Actinic keratosis and beyond...

CHAIR: Markus Heppt, Erlangen, Germany

Marco Ardigo, Rozzano, Italy

16:15–16:30 **Patient understanding is first...**

Markus Heppt, Erlangen, Germany

16:30–16:45 **... Lesion characterization is key**

Marco Ardigo, Rozzano, Italy

SATELLITE SYMPOSIA PROGRAM

FRIDAY, APRIL 4TH, 2025



Mitropoulos Hall 08:30–09:30

SILVER SPONSOR SATELLITE SYMPOSIUM **SAT07**

**Optimizing Actinic Keratosis Treatment:
Expert Tips and Proven Strategies with 4% 5-FU**

CHAIR: Aimilios Lallas, Thessaloniki, Greece

08:30–08:32 **Introduction**

Aimilios Lallas, Thessaloniki, Greece

08:32–08:47 **Management of Actinic keratosis:**

Positioning of the 5-FU in the European guidelines

Markus Heppt, Erlangen, Germany

08:47–09:02 **Optimizing Actinic Keratosis Treatment with 4% 5-Fluorouracil:
Key Findings from the Dose-Ranging Study**

Claas Ulrich, Berlin, Germany

09:02–09:07 **Transition**

Aimilios Lallas, Thessaloniki, Greece

09:07–09:22 **Expert Consensus on Actinic Keratosis Management:
Insights from the Delphi Study**

Giuseppe Argenziano, Naples, Italy

09:22–09:27 **Q&A Session**

Claas Ulrich, Berlin, Germany

Giuseppe Argenziano, Naples, Italy

09:27–09:30 **Closing remarks**

Aimilios Lallas, Thessaloniki, Greece

IMMUNOCORE

Banqueting Hall 09:30–10:30

GOLD SPONSOR SATELLITE SYMPOSIUM **SAT08**

Evolving ImmTAC therapy in melanoma

09:30–09:35 **Welcome and Introduction**

Chair

09:35–09:45 **Development of the ImmTAC platform – a translational
perspective**

09:45–10:00 **ImmTAC in the clinic – lessons learnt from metastatic Uveal
Melanoma (mUM)**

10:00–10:15 **ImmTAC in melanoma – where do we go next ?**

10:15–10:30 **Panel Discussion**



Mitropoulos Hall 11:00-12:00
FURTHER SPONSOR SATELLITE SYMPOSIUM **SAT09**

To be announced



Trianti Hall 12:00-13:00
PLATINUM SPONSOR SATELLITE SYMPOSIUM **SAT101**

To be announced

REGENERON

Trianti Hall 15:00-16:00
PLATINUM SPONSOR SATELLITE SYMPOSIUM **SAT11**

To be announced



Mitropoulos Hall 16:30-17:30
FURTHER SPONSOR SATELLITE SYMPOSIUM **SAT12**

To be announced

Mitropoulos Hall 17:30-18:30
FURTHER SPONSOR SATELLITE SYMPOSIUM **SAT13**

To be announced

SATELLITE SYMPOSIA PROGRAM

SATURDAY, APRIL 5TH, 2025

Mitropoulos Hall 09:00–10:00

FURTHER SPONSOR SATELLITE SYMPOSIUM **SAT14**

To be announced

Mitropoulos Hall 11:30–12:30

FURTHER SPONSOR SATELLITE SYMPOSIUM **SAT15**

To be announced

Mitropoulos Hall 14:15–15:15

FURTHER SPONSOR SATELLITE SYMPOSIUM **SAT16**

To be announced

Mitropoulos Hall 15:15–16:15

FURTHER SPONSOR SATELLITE SYMPOSIUM **SAT17**

To be announced

